GB1580201A - Prostaglandin analogues - Google Patents
Prostaglandin analogues Download PDFInfo
- Publication number
- GB1580201A GB1580201A GB10118/76A GB1011876A GB1580201A GB 1580201 A GB1580201 A GB 1580201A GB 10118/76 A GB10118/76 A GB 10118/76A GB 1011876 A GB1011876 A GB 1011876A GB 1580201 A GB1580201 A GB 1580201A
- Authority
- GB
- United Kingdom
- Prior art keywords
- trans
- cis
- general formula
- double bond
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 title claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 252
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 114
- 239000000243 solution Substances 0.000 claims description 103
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- 238000006243 chemical reaction Methods 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 73
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 62
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 55
- -1 olive oil Chemical compound 0.000 claims description 51
- 125000004432 carbon atom Chemical group C* 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 239000003960 organic solvent Substances 0.000 claims description 39
- 239000002904 solvent Substances 0.000 claims description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 35
- 238000004809 thin layer chromatography Methods 0.000 claims description 35
- 239000007864 aqueous solution Substances 0.000 claims description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 31
- 230000008569 process Effects 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000741 silica gel Substances 0.000 claims description 27
- 229910002027 silica gel Inorganic materials 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 26
- 150000003180 prostaglandins Chemical class 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 22
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 21
- 239000005977 Ethylene Substances 0.000 claims description 21
- 229920000858 Cyclodextrin Polymers 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 16
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 16
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- 230000007062 hydrolysis Effects 0.000 claims description 13
- 238000006460 hydrolysis reaction Methods 0.000 claims description 13
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 10
- 231100000252 nontoxic Toxicity 0.000 claims description 10
- 230000003000 nontoxic effect Effects 0.000 claims description 10
- 230000003301 hydrolyzing effect Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 7
- 150000007513 acids Chemical class 0.000 claims description 7
- 230000035935 pregnancy Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000008247 solid mixture Substances 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 230000012173 estrus Effects 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 231100000176 abortion Toxicity 0.000 claims description 4
- 206010000210 abortion Diseases 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 231100000502 fertility decrease Toxicity 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 230000002175 menstrual effect Effects 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 150000002642 lithium compounds Chemical class 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 239000012457 nonaqueous media Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 150000002895 organic esters Chemical class 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 239000008016 pharmaceutical coating Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000008223 sterile water Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 2
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 39
- 150000004702 methyl esters Chemical class 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 19
- 239000007788 liquid Substances 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 14
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 14
- 239000003480 eluent Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 7
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 7
- 229910052744 lithium Inorganic materials 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 150000003512 tertiary amines Chemical class 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 125000002723 alicyclic group Chemical group 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 238000007239 Wittig reaction Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- YWWZCHLUQSHMCL-UHFFFAOYSA-N diphenyl diselenide Chemical compound C=1C=CC=CC=1[Se][Se]C1=CC=CC=C1 YWWZCHLUQSHMCL-UHFFFAOYSA-N 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- AITHRLYLAMRNSQ-UHFFFAOYSA-N 5-(triphenyl-$l^{5}-phosphanylidene)pentanoic acid Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CCCCC(=O)O)C1=CC=CC=C1 AITHRLYLAMRNSQ-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004015 abortifacient agent Substances 0.000 description 3
- 231100000641 abortifacient agent Toxicity 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- FNAYMVBPGIKMCB-UHFFFAOYSA-N chloroform;2-(oxolan-2-yl)acetic acid Chemical compound ClC(Cl)Cl.OC(=O)CC1CCCO1 FNAYMVBPGIKMCB-UHFFFAOYSA-N 0.000 description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 3
- 229940117975 chromium trioxide Drugs 0.000 description 3
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 3
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 230000003529 luteolytic effect Effects 0.000 description 3
- LCEFEIBEOBPPSJ-UHFFFAOYSA-N phenyl selenohypobromite Chemical compound Br[Se]C1=CC=CC=C1 LCEFEIBEOBPPSJ-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 2
- VTHIKKVKIVQWHV-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridine Chemical compound [O-2].[O-2].[O-2].[Cr+6].C1=CC=NC=C1 VTHIKKVKIVQWHV-UHFFFAOYSA-N 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 150000002901 organomagnesium compounds Chemical class 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 239000005297 pyrex Substances 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NYYLZXREFNYPKB-UHFFFAOYSA-N 1-[ethoxy(methyl)phosphoryl]oxyethane Chemical compound CCOP(C)(=O)OCC NYYLZXREFNYPKB-UHFFFAOYSA-N 0.000 description 1
- QDOMKUJILDCPEW-UHFFFAOYSA-N 1-chloropyrrolidine-2,5-dione;methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1.ClN1C(=O)CCC1=O QDOMKUJILDCPEW-UHFFFAOYSA-N 0.000 description 1
- YCQANBSROMMIQP-UHFFFAOYSA-N 1-chloropyrrolidine-2,5-dione;methylsulfanylmethane Chemical compound CSC.ClN1C(=O)CCC1=O YCQANBSROMMIQP-UHFFFAOYSA-N 0.000 description 1
- NQTSTBMCCAVWOS-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-phenoxypropan-2-one Chemical compound COP(=O)(OC)CC(=O)COC1=CC=CC=C1 NQTSTBMCCAVWOS-UHFFFAOYSA-N 0.000 description 1
- CQCAYWAIRTVXIY-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetaldehyde Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC=O)C1=CC=CC=C1 CQCAYWAIRTVXIY-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- UZGMBPGJYMWXPS-UHFFFAOYSA-N [Cl].CSC1=CC=CC=C1 Chemical compound [Cl].CSC1=CC=CC=C1 UZGMBPGJYMWXPS-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000004808 allyl alcohols Chemical group 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003243 anti-lipolytic effect Effects 0.000 description 1
- 230000000085 anti-nidation effect Effects 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 150000001940 cyclopentanes Chemical class 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZJULYDCRWUEPTK-UHFFFAOYSA-N dichloromethyl Chemical compound Cl[CH]Cl ZJULYDCRWUEPTK-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical compound C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- LSYBEKRLBPCVES-UHFFFAOYSA-N ethyl acetate formic acid Chemical compound C(C)(=O)OCC.C(=O)O.C(=O)O LSYBEKRLBPCVES-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000002863 oxytocic agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000007699 photoisomerization reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- JXHZRQHZVYDRGX-UHFFFAOYSA-M sodium;hydrogen sulfate;hydrate Chemical compound [OH-].[Na+].OS(O)(=O)=O JXHZRQHZVYDRGX-UHFFFAOYSA-M 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- GTCDARUMAMVCRO-UHFFFAOYSA-M tetraethylazanium;acetate Chemical compound CC([O-])=O.CC[N+](CC)(CC)CC GTCDARUMAMVCRO-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
(54) PROSTAGLANDIN ANALOGUES
(71) We, ONO PHARMACEUTICAL CO. LTD., a Japanese Body
Corporate of, 14 Doshomachi 2-Chome, Higashiku, Osaka 541, Japan, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- This invention is concerned with new prostaglandin analogues.
Prostaglandins are derivatives of prostanoic acid which has the following formula:
Various types of prostaglandins are known, the types depending inter alia on the structure and substituents on the alicyclic ring. For example, the alicyclic rings of prostaglandins F(PGF) and E(PGE) have the structures:
respectively. In the foregoing formulae and in other formulae throughout this specification the dotted lines denote, in accordance with generally accepted rules of nomenclature, that the attached grouping lies behind the general plane of the ring system, i.e. that the grouping is in a-configuration, the thickened lines denote that the grouping lies in front of the general plane of the system, i.e. that the grouping is in pconfiguration, and the wavy linea indicates that the grouping is in a- or p-configuration.
Such compounds are sub-classified according to the position of double bond(s) in the side chain(s) attached to the 8- and 12-positions of the alicyclic ring. Thus
PGI compounds have a trans-double bond between C,3Cl4(trans-A'3) and PG2 compounds have a cis-double bond between C5-C8 and a trans-double bond between C13-C14(cis-A5, trans-A13). For example, prostaglandin Fia (PGF"t) and prostaglandin E1 (PGE,) are characterized by the following structures IV and V.
respectively. The structures of PGF2Q and PGE2, as members of the PG2 group correspond to those of formulae IV and V respectively with a cis-double bond between the carbon atoms in positions 5 and 6. Compounds in which the double bond between the carbon atoms in positions 13 and 14 of members of the PG, group is replaced by ethylene are known as dihydroprostaglandins, e.g. dihydroprostaglandin Fia (dihydro-PGF,Q) and dihydro-prostaglandin E, (dihydro-PGE,).
Moreover, when one or more methylene groups are added to, or eliminated from, the aliphatic group attached to the 12-position of the alicyclic ring of the prostaglandins the compounds are known, in accordance with the usual rules of organic nomenclature, as homo-prostaglandins (methylene group added) or norprostaglandins (methylene group eliminated), and, when more than one methylene group is added or eliminated, the number is indicated by di- tri- etc. before the prefix "homo" or "nor".
Prostaglandins are generally known to possess pharmacological properties, for example they stimulate smooth muscle, have hypotensive, diuretic, bronchodilating and antilipolytic activities, and also inhibit blood platelet aggregation and gastric acid secretion, and are, accordingly, useful in the treatment of hypertension, thrombosis, asthma and gastro-intestinal ulcers, in the induction of labour an abortion in pregnant female mammals, in the prevention of arteriosclerosis, and as diuretic agents. They are fat-soluble substances obtainable in very small quantities from various tissues of animals which secrete the prostaglandins in the living body.
For example, PGEs have an inhibiting effect on gastric acid secretion and may, accordingly, be used in the treatment of gastric ulcers. They also inhibit the release of free fatty acid induced by epinephrine and as a result they reduce the concentration of free fatty acid in blood, and are, accordingly, useful in the prevention of arteriosclerosis and hyperlipemia, PGE, inhibits blood platelet aggregation and also removes the thrombus and prevents thrombosis. PGEs and
PGFs have a stimulating effect on smooth muscle and increase the intestinal peristalsis; these actions indicate therapeutic utility on post-operative ileus and as purgatives. Furthermore, PGEs and PGFs may be used as oxytocics, as abortifacients in the first and second trimesters; in the post-labour abortion of the placenta, nad as oral contraceptives because they regulate the sexual cycle of female mammals. PGEs have vasodilator and diuretic activities. PGEs are useful for improvement in patients suffering from cerebral vascular disease because they increase the cerebral blood flow and are also useful in the treatment of asthmatic conditions in patients because of their bronchodilating activity.
During the past decade widespread investigations have been carried out in order to discover inter alia new products possessing the pharmacological properties of the "natural" prostaglandins or one or more of such properties to an enhanced degree, or hitherto unknown pharmacological properties. It has now been found that by introducing a double bond between the carbon atoms in the 3- and 4positions of prostaglandins F2Q and E2 and certain analogues thereof, the pharmacological properties of the "natural" prostaglandins are, in some aspects of their activities, improved or modified.
The present invention accordingly provides new prostaglandin analogues of the general formula:
[wherein X represents cis or trans-vinylene (i.e. -CH--CH-), or ethylene (i.e. ICH2CH2-), Z represents
R' represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 (preferably 1 to 4) carbon atoms, R2 represents a methyl group or, preferably, a hydrogen atom, R3 represents a straight- or branched-chain alkylene group containing from I to 7 (preferably 1 or 2) carbon atoms and R4 represents a cycloalkyl group containing from 5 to 7 carbon atoms, a grouping of the formula:
(wherein R5 and R6, which may be the same or different, each represent a hydrogen atom or halogen atom, a trifluoromethyl group or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms), or a grouping of the formula:
(wherein R5 and R8 are as hereinbefore defined), or R3 and R4 together represent a straight- or branched-chain alkyl group containing from 1 to 10 carbon atoms; and (1) the double bond between C3-C4 is trans or cis, or trans and cis, when X is cisvinylene or ethylene and (2) the double bond between C-C4 is trans, when X is trans-vinylene, and the double bond between C,3C,4is trans, with the exclusion of those prostaglandin analogues wherein X represents cis-vinylene or ethylene, Z represents C=O, R' and R2 represents hydrogen atoms, R3 and R4 together represent n-pentyl and the double bond between C3-C4 is trans] and cyclodextrin clathrates of such acids and esters, and when R' represents a hydrogen atom, nontoxic (e.g. sodium) salts thereof.
It is to be understood that in subsequent formulae appearing in this specification the C13-C14 double bond is trans.
Preferred compounds of general formula VI are those wherein R' represents a hydrogen atom or a methyl group; preferably R2 represents a hydrogen atom, preferably R3 represents methylene (i.e. -CH2-) or ethylene, preferably R4 represents a grouping of formula VII or VIII in which R5 preferably represents a hydrogen atom and R8 preferably represents a hydrogen atom or a chlorine atom or a trifluoromethyl group, or preferably R3 and R4 together represent a pentyl or l,l-dimethylpentyl group, and preferably the hydroxy groups depicted in formula
VI in a- or p-configuration are attached to the carbon atom in a-configuration.
The present invention is concerned with all compounds of general formula VI in the "natural" form or its enantiomeric form, or mixtures thereof, more particularly the racemic form consisting of equimolecular mixtures of natural and its enantiomeric form.
As will be apparent to those skilled in the art, the compounds depicted in general formula VI have at least four centres of chirality, these four centres of chirality being at the alicyclic ring carbon atoms identified as 8, 11 and 12 and at the C--15 carbon atom which has attached to it a hydroxy group. A further centre of chirality occurs when the symbol Z represents
and further centres of chirality may occur in groups represented by the symbols R', R3 and R4. The presence of chirality leads, as is well known, to the existence of isomerism. However, the compounds of general formula VI all have such a configuration that the side-chains attached to the ring carbon atoms in the positions identified as 8 and 12 are trans with respect to each other. Accordingly, all isomers of general formula VI, and mixtures thereof, which hve those side-chains attached to the ring carbon atoms in positions 8 and 12 in the trans-configuration and have hydroxy group as depicted in the 15-position are to be considered within the scope of general formula VI.
According to a feature of the present invention, the prostaglandin analogues of general formula VI, wherein X represents cis-vinylene or ethylene, R' represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms and the other symbols are as hereinbefore defined, i.e. compounds of the general formula:
(wherein Y represents cis-vinylene or ethylene, R7 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms, preferably a methyl group, the other symbols are as hereinbefore defined and the double bond between C3-C4 is trans or cis, or trans and cis) are prepared by the process which comprises hydrolysing a cyclopentane derivative of the general formula:
(wherein R8 represents a 2-tetrahydrofuranyl group or a l-ethoxyethyl group or a 2tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group, R9 represents a hydrogen atom or a 2-tetrahydrofuranyl group or a I-ethoxyethyl group or a 2-tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group, R1 being other than hydrogen when Z represents
the other symbols are as hereinbefore defined and the double bond between C3-C4 is trans or cis, or trans and cis) to convert to a hydroxy group the group ORB and, when R9 is other than a hydrogen atom, the group OR9 to obtain a PGF or PGE compound of general formula IX.
It is to be understood that in subsequent formulae appearing in this specification the double bond between C3-C4 in the grouping
attached to the cyclopentane ring is as specified above in relation to compounds of general formulae IX and X.
The groups ORB and OR9 (when R9 is other than a hydrogen atom) of compounds of general formula X (preferably such groups are 2-tetrahydropyranyl) may be converted to hydroxy groups by mild hydrolysis (I) with an aqueous solution of an organic acid such as acetic acid, propionic acid, oxalic acid, or ptoluenesulphonic acid, or an aqueous solution of an inorganic acid such as hydrochloric acid or sulphuric acid advantageously in the presence of an inert organic solvent miscible with water, e.g. a lower alkanol such as methanol or ethanol, preferably methanol, or an ether such as l,2-dimethoxyethane, dioxan, or tetrahydrofuran, preferably tetrahydrofuran, at a temperature ranging from ambient to 750C (preferably at a temperature below 45"C), or (2) with an anhydrous solution of an organic acid such as p-toluenesulphonic acid or trifluoroacetic acid in a lower alkanol such as methanol or ethanol at a temperature ranging from 10 to 450C. Advantageously the mild hydrolysis may be carried out with a mixture of hydrochloric acid, water and tetrahydrofuran or methanol, a mixture of acetic acid, water and tetrahydrofuran, or a mixture of ptoluenesulphonic acid and methanol. The products of general formula IX may be purified by column chromatography on silica gel, which procedure may, when the starting material of general formula X is a mixture of compounds with the group
OR9 in the 15-position in a- and pconfiguration, lead to a separation of the resulting ISa-hydroxy and 15p-hydroxy isomers of general formula IX.
The products of general formula IX may be separated by thin layer chromatography on silica gel pre-treated with silver nitrate using an inert organic solvent medium, e.g. chloroform and methanol, or chloroform and ethanol, as developing solvent to give the trans-3 and cis-53 prostaglandin analogues of general formula IX.
Compounds of general formula X, wherein R9 and R9 each represent a 2tetrahydrofuranyl group or a l-ethoxyethyl group or a 2-tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group and Z represents
[hereinafter depicted in general formula XB], may be prepared from compounds of general formula X, wherein R9 and R9 each represent a 2-tetrahydrofuranyl group or a l-ethoxyethyl group or a 2-tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group and Z represents
by methods known per se for the conversion of a hydroxy group in the 9-position of a prostaglandin compound to an oxo group, for example by mens of a chromic acid solution (e.g. obtained from chromium trioxide, manganese sulphate and sulphuric acid in water) or Jones' reagent or Collins' reagent or dimethylsulphide-Nchlorosuccinimide complex [cf. J. Amer. Chem. Soc., 94 7586 (1972)], at a moderately low temperature. By the term "methods known per se" as used in this specification is meant methods heretofore used or described in the chemical literature.
Compounds of general formula X, wherein Z represents
and the other symbols are as hereinbefore defined, i.e. compounds of the general formula:
(wherein the various symbols are as hereinbefore defined) may be prepared from compounds of the general formula:
(wherein the various symbols are as hereinbefore defined, and the double bond between C2-C3 is trans) by (i) reaction with an alkali metal, e.g. sodium or potassium, hydroxide or carbonate in the presence of an inert organic solvent, e.g.
an alkanol containing from I to 4 carbon atoms, e.g. methanol or ethanol, at a temperature ranging from ambient to 200 C., or (ii) reaction with equimolecular quantities of a lithium compound of the general formula:
(wherein R'O and R1', which may be the same or different, each represent a straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms or a cycloalkyl group containing from 3 to 6 carbon atoms), e.g. lithium diisopropylamide, and hexamethylphosphoramide in the presence of an inert organic solvent, e.g. tetrahydrofuran, at a low temperature, e.g. -70"C.
Compounds of general formula IX, wherein Z represents
and the other symbols are as hereinbefore defined, i.e. compounds of general formula:
(wherein the various symbols are as hereinbefore defined) are also prepared, according to another feature of the invention, from compounds of the general formula:
(wherein the various symbols are as hereinbefore defined, and the double bond between C2-C3 is trans) by the process described above for the preparation of compounds of formula XA from compounds of formula XI.
The compounds of formula IXA may be separated by thin layer chromatography on silica gel pre-treated with silver nitrate using an inert organic solvent medium, e.g. chloroform and methanol, or chloroform and ethanol, as developing solvent to give the transA3 and cisA3 prostaglandin analogues of general formula IXA.
Compounds of general formula XIII, wherein the various symbols are as hereinbefore defined, may be prepared from compounds of general formula XI by the procedures hereinbefore described for the conversion of compounds of general formula X into compounds of general formula IX.
Compounds of general formula IX, wherein Z represents
and the other symbols are as hereinbefore defined, i.e. compounds of the general formula:
(wherein the various symbols are as hereinbefore defined) are prepared, according to a still further feature of the invention, by the process which comprises hydrolysing the silyloxy groups of a compound of the general formula:
(wherein TMS represents the trimethylsilyl group, and the other symbols are as hereinbefore defined) to hydroxy groups under extremely mild acidic conditions, for example by treatment of a solution of such a compound in an inert organic solvent, e.g. ethyl acetate or diethyl ether, with an aqueous oxalic acid solution, preferably at room temperature.
Compounds of general formula XIV may be prepared by oxidation of compounds of the general formula:
(wherein the various symbols are as hereinbefore defined) with Collins' reagent (chromium trioxide-pyridine complex) in the presence of an inert organic solvent, e.g. methylene chloride, preferably at a temperature of about 10"C, or with dimethylsulphide-N-chlorosuccinimide complex at 0 to -300C [cf. E.J. Corey and
C.U. Kim, J. Amer. Chem. Soc., 94, 7586 (1972].
Compounds of general formula XV may be prepared from compounds of general formula IXA by reaction with a suitable trimethylsilylating agent, e.g. Ntrimethylsilyldiethylamine or N,O-bis(trimethylsilyl)acetamide, in acetone, preferably at room temperature.
Compounds of general formula XI, wherein the various symbols are as hereinbefore defined, may be prepared by the process which comprises reacting a compound of the general formula:
(wherein the various symbols are as hereinbefore defined) with a compound of general formula XII, wherein the various symbols are as hereinbefore defined, to obtain a lithium enolate of the general formula:
when R7 is a hydrogen atom) (or OLi when R9 is a hydrogen atom) (wherein the various symbols are as hereinbefore defined) reacting the lithium enolate with benzeneselenenyl bromide (i.e. CfHsSeBr), or diphenyl diselenide, or a dialkyl disulphide or diphenyl disulphide of general formula R'2SSR12, wherein
R12 represents an alkyl group containing from 1 to 4 carbon atoms or a phenyl group, hydrolysing the resulting intermediate to obtain a compound of the general formula:
(wherein Q represents a group -SeC9H5 or a group -SR12, in which R12 is as hereinbefore defined, and the other symbols are as hereinbefore defined), treating the resulting compound with hydrogen peroxide or sodium periodate, and decomposing the resulting compound of the general formula:
(wherein the various symbols are as hereinbefore defined) to convert the grouping
attached to the 8-position of the cyclopentane ring to a trans A3, grouping
wherein R7 is as hereinbefore defined.
The reaction between compounds of general formula XVI and lithiated amines of general formula XII is carried out in an organic solvent medium, for example, when R7 represents an alkyl group, by adding dropwise a solution of an ester of general formula XVI in tetrahydrofuran to a solution of an amine of general formula XII in tetrahydrofuran at a low temperature, w.g. -78"C, or, when R7 represents a hydrogen atom, adding dropwise a solution of an acid of general formula XVI in tetrahydrofuran to a solution of an amine of general formula XII in tetrahydrofuran at a low temperature in the presence of hexamethylphosphoramide at OOC, the ratio of the molecular equivalents of compounds of general formula XVI to XII in the reaction mixture being suitably adjusted to obtain a lithium enolate of general formula XVII. In the case where a prostaglandin ester is employed as reactant, after completion of the addition of the prostaglandin solution to the amine solution, the reaction mixture is stirred at the same temperature for about 30 minutes to obtain a solution of the lithium enolate of general formula XVII. In the case where a prostaglandin acid is employed as reactant (R7 represents a hydrogen atom), the reaction mixture is stirred at room temperature for about 30 minutes to obtain a solution of the lithium enolate of general formula XVII.
The reaction between the lithium enolate of general formula XVII and benzeneselenenyl bromide, diphenyl diselenide or a dialkyl or diphenyl disulphide, is preferably carried out in tetrahydrofuran, hexamethylphosphoramide, diethyl ether, n-hexane or n-pentane or a mixture of two or more of them, tetrahydrofuran being the preferred solvent medium, at a low temperature when R7 in formula XVII represents an alkyl group, e.g. -780C, or, when R7 in formula XVII represents a hydrogen atom, at OOC. Thus, to the lithium enolate solution obtained as described above there is added a solution in tetrahydrofuran of benzeneselenenyl bromide, diphenyl diselenide or a dialkyl or diphenyl disulphide, the temperature of the two solutions being -78"C or 0 C according to whether an ester or acid of formula
XVII respectively, is the reactant. The reaction mixture is then stirred (when R7 in formula XVII is an alkyl group) at -780C (a) for one hour when a selenium compound is the reactant or (b) for 30 minutes when a disulphide is the reactant, and subsequently at ambient temperature, e.g. 15"C for 30 minutes, or (when R7 in formula XVII is a hydrogen atom) at room temperature for I hour 30 minutes.
After addition of, for example, a small amount of a saturated aqueous ammonium chloride solution to the solution of the resulting prostaglandin intermediate to hydrolyze it, the product of formula XVIII is extracted with ethyl acetate.
If desired, the intermediate esters of general formula XVIII wherein R7 represents an alkyl group may be converted to corresponding acids of general formula XVIII, i.e. R7 represents a hydrogen atom, by hydrolysis under alkaline conditions. The hydrolysis of the esters under alkaline conditions may be effected with an aqueous solution of an alkali metal, e.g. sodium or potassium, hydroxide or carbonate in the presence of a water-miscible organic solvent, e.g. tetrahydrofuran or an alkanol containing from I to 4 carbon atoms, e.g. methanol.
When the product of formula XVIII is a compound wherein Q represents Se, 8 representing the phenyl radical, the product is then treated with 5 to 7 molecular equivalents of hydrogen peroxide in a mixture of ethyl acetate and tetrahydrofuran or methanol at a temperature of 30"C or below, or with 5 molecular equivalents of sodium periodate in the presence of a lower alkanol, preferably methanol, and water, at a temperature below 20"C, preferably for about 24 hours, to form a compound of formula XIX wherein O--Q- represents -Se(O, and stirring of the reaction mixture at a temperature of 25 to 300C for one hour results in decomposition of the compound to a transh2-prostaglandin analogue of general formula XI, which can be separated from the reaction medium by methods known per se and, if desired, purified by column chromatography on silica gel.
When the product of formula XVIII is a compound wherein Q is a group -SR12, R12 being as hereinbefore defined, the product is treated with hydrogen peroxide or sodium periodate in the same way as hereinbefore described for a product of formula XVIII wherein Q is benzeneselenenyl to obtain a compound of general formula XIX wherein Q is a group --SR'2, R12 being as hereinbefore defined, which can be separated from the reaction medium by methods known per se.
When the compound of formula XIX is one wherein Q represents an alkylthio group containing from I to 4 carbon atoms, i.e. a group -SR12, (wherein R12' represents an alkyl group containing from I to 4 carbon atoms), the compound is dissolved in toluene and the solution stirred, preferably in the presence of a small amount of calcium carbonate, at a temperature of 100" to 1200C for a period ranging from 5 to 24 hours to decompose the compound of a transA2-prostaglandin analogue of general formula XI. When the compound of general formula XIX is one wherein Q represents the phenylthio group, the compound is dissolved in carbon tetrachloride and the solution stirred, preferably in the presence of a small amount of calcium carbonate, at a temperature of about 50"C for a period ranging from 5 to 24 hours to decompose the compound to a transA2-prostaglandin analogue of general formula XI.
The methods hereinbefore described for the preparation of prostaglandin analogues of general formula IX may be represented by the series of reactions depicted schematically below in Scheme A, wherein R9, represents a 2tetrahydrofuranyl group, a l-ethoxyethyl group, or a 2-tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group, and the other symbols are as hereinbefore defined.
SCHEME A
SCHEME A (Continued)
(XI) (XIII) ,OH ; COOR7 OH t.3 ,N/H=CH \/ ,OOR' R2 ~~~~~~~~~ 8 R3 R4 < 3 R3- R4 OR OR OH H (XA) when R9 is other than a hydrogen atom i / \ / pH Ny/H=CM/COOR7 l'\/CH=C\/COOR7 2 R2 oR8 OR OTMS OTMS R3-R4 Oms (XB) (XV) ot } cooR7 COOT7 CH=CH < COOR7 J OH OH w R23 ~ R4 OTMS (IXB) (XIV) The starting materials of general formula XVI, wherein R9 represents a 2tetrahydrofuranyl group or a I-ethoxyethyl group or a 2-tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group and the other symbols are as hereinbefore defined, may be prepared by the sequence of reactions hereinafter depicted schematically in Scheme B:
SCHEME B
SCHEME B (Continued)
wherein Ac represents the acetyl group, R'3 represents a straight- or branchedchain alkyl group containing from 1 to 4 carbon atoms, R'4 represents a straight- or branched-chain alkyl group containing from I to 4 carbon atoms, and the other
symbols are as hereinbefore defined.
The starting compound of formula XX, wherein the group OAc is in a
configuration, may be prepared as described in J. Amer. Chem. Soc., 91, 5675
(1969) and ibid 92, 397 (1970) by E.J. Corey et aL
A method for the preparation of the bicyclo-octane starting materials of
formula XX, wherein the group OAc is in p-configuration, utilizing known
procedures may be represented by the series of reactions depicted schematically
below in Scheme C [cf. EJ. Corey and Shiro Terashima, Tetrahedron Letters, No.
2, 111-113(1972)].
SCHEME C
wherein Ts represents the tosyl group and Ac is as hereinbefore defined. The various reactions depicted above in Scheme C may be effected by known methods.
A compound of formula XXX may be prepared by reacting a compound of formula
XXIX with tetraethylammonium acetate.
A compound of formula XX may be converted to a compound of formula XXI by oxidation under mild conditions, e.g. with Collins' reagent, Jones' reagent, dimethyl or methyl phenyl sulphide-N-chlorosuccinimide complex, dimethyl or methyl phenyl sulphide-chlorine complex [cf. J. Amer. Chem. Soc., 9
Compounds of general formula XXVI may be prepared from compounds of general formula XXV by reaction with a dihydropyran, dihydrofuran or ethyl vinyl ether in an inert organic solvent, e.g. methylene chloride, in the presence of a condensing agent, e.g. p-toluenesulphonic acid.
Compounds of general formula XXVII may be prepared by reducing to a hydroxy group the oxo group of compounds of general formula XXVI with diisobutyl aluminium hydride in toluene for about 15 minutes at -600C.
Compounds of general formula XVIA may be prepared fromc ompounds of general formula XXVII by reaction with (4-carboxybutylidene)triphenylphosphorane of formula (CssH5)3P=CHHCH2)3COOH. The reaction between the bicyclooctane of general formula XXVI I and (4-carboxybutylidene)triphenylphosphorane [obtained by the reaction of sodium methylsulphinylmethylide with (4-carboxybutyl)triphenylphosphonium bromide] is carried out under the normal conditions utilized for the Wittig reaction, e.g. in an inert organic solvent at ambient temperature. The reaction is preferably carried out in dimethyl sulphoxide because the phosphorane compound is practically insoluble in other solvents, e.g. tetrahydrofuran, and because a cis-double bond must be formed stereospecifically in the Wittig reaction.
For the better performance of the Wittig reaction more than two molecular equivalents of the phosphorane compound are required for each mole of the bicyclooctane reactant. The reaction is generally effected at a temperature of 100 to 600 C, preferably at 200 to 300 C, and Is usually complete after about 30 minutes to four hours at laboratory temperature. The acid product of formula XVIA may be extracted from the reaction mixture by conventional procedures and further purified by column chromatography on silica gel.
If desired, compounds of general formula XVIB may be prepared from compounds of general formula XVIA by esterification, for example by reaction with (i) appropriate diazoalkane compounds, e.g. diazomethane in an inert organic solvent, e.g. diethyl ether, at a temperature of -100C to 250C, preferably at OOC, (ii) appropriate alcohols in the presence of dicyclohexylcarbodiimide as a condensing agent, (iii) appropriate alcohols following the formation of a mixed acid anhydride by adding a tertiary amine and then a pivaloyl halide or an arylsulphonyl or alkylsulphonyl halide (cf. our British Patent Specification Nos. 1,362,956 and 1,364,125), (iv) alkyl halides, e.g. methyl iodide, and (a) potassium carbonate in acetone [cf. J. Org. Chem., 34, 3717 (1969)], (b) sodium bicarbonate in N,Ndimethylacetamide or N,N-dimethylformamide [cf. Advan. Org. Chem., 5, 37 (1965)], or (c) calcium oxide in dimethyl sulphoxide [cf. Synthesis, 262 (1972)], or (v) N,N-dimethylformamide-dialkylacetals, e.g. N,N-dimethylformamidedimethylacetal, in dry benzene [cf. Helv. Chim., Acta, 48, 1746 (1965)]. If desired, compounds of general formula XVIA and XVIB may be reduced to give compounds of general formula XVIC. Suitably the reduction may be effected by hydrogenation in the presence of a hydrogenation catalyst, e.g. palladium on carbon or palladium black, in an inert organic solvent, for example a lower alkanol, e.g. methanol or ethanol, at laboratory temperature at normal or elevated pressure, e.g. at a hydrogen pressure from atmospheric to 15 kg/cm2.
The dialkyl phosphonates of general formula XXII may be prepared by reacting a solution of n-butyllithium in an inert organic solvent, e.g. n-hexane, npentane or diethyl ether, with a solution of a dialkyl methylphosphonate of the general formula:
(wherein R13 is as hereinbefore defined), e.g. dimethyl methylphosphonate or diethyl methylphosphonate, at a temperature below -50"C, and then adding dropwise to the reaction mixture a solution of a compound of the general formula:
(wherein R3 and R4 are as hereinbefore defined and R represents a lower alkyl group, preferably containing from I to 4 carbon atoms, e.g. methyl or ethyl) in tetrahydrofuran at a temperature below -50"C, stirring the reaction mixture below -500C, for 1.5 hours and then stirring for 18 hours at 0 C to give the desired dialkyl phosphonate of general formula XXII.
Compounds of general formula XVI, wherein Rg represents a hydrogen atom and the other symbols are as hereinbefore defined, may be prepared by the hydrolysis under alkaline conditions of compounds of the general formula:
wherein RIB represents an alkanoyl group containing from 2 to 5 carbon atoms and the other symbols are as hereinbefore defined. The hydrolysis under alkaline conditions may be effected with (1) an aqueous solution of-an alkali metal, e.g.
sodium or potassium, hydroxide or carbonate in the presence of a water miscible solvent, e.g. tetrahydrofuran or an alkanol containing from I to 4 carbon atoms, to give compounds of general formula XVI wherein R' represents a hydrogen atom, or (2) with anhydrous potassium carbonate in an anhydrous alkanol containing from I to 4 carbon atoms, preferably absolute methanol, to give compounds of general formula XVI wherein R7 represents an alkyl group containing from 1 to 4 carbon atoms.
Compounds of general formula XXXIII may be prepared from compounds of the general formula:
(wherein the various symbols are as hereinbefore defined) by converting the 15-oxo group to a hydroxy group by methods known per se. The conversion may be carried out by means heretofore mentioned for the conversion of compounds of general formula XXIII to those of general formulae XXIVA and XXIVB. The product of general formula XXXIII thus obtained is a mixture of isomers in which the hydroxy group at position 15 is in a- or p-configuration. If desired, the isomer having the hydroxy group in a-configuration may be separated from the isomer having the hydroxy group in p-configuration by column chromatography on silica gel. The separated isomers may be utilized in the procedures herein described to give prostaglandin analogues of general formula VI in which the hydroxy group in position 15 is in er- or p-configuration.
Compounds of general formula XXXIV, wherein the various symbols are as hereinbefore defined, may be prepared by the Wittig reaction of a compound of the general formula:
(wherein the various symbols are as hereinbefore defined) with the sodio derivative of a dialkyl phosphonate of general formula XXII, wherein the various symbols are as hereinbefore defined, preferably using the same reaction conditions as are mentioned heretofore for the reaction of compounds of general formula XXI with those of general formula XXII.
Compounds of general formula XXXV, wherein the various symbols are as hereinbefore defined, used as starting materials in the hereinbefore described procedure, may themselves be prepared by methods known per se from compounds of general formula XXXVI by the series of reactions depicted schematically below in Scheme D:
SCHEME D
wherein Y, Ra, R14 and RIB are as hereinbefore defined and preferably RIB represents an acetyl group.
Compounds of general formula XXXVII may be prepared by reacting compounds of general formula XXXVI with trimethylchlorosilane in an inert organic solvent, e.g. methylene chloride, in the presence of a base, e.g. pyridine or a tertiary amine, at a low temperature, e.g. at a temperature of -30"C to OOC.
Compounds of general formula XXXVIII may be prepared by reacting a trimethylsilyl ether of general formula XXXVI I with an appropriate acyl chloride or acid anhydride in an inert organic solvent, e.g. methylene chloride, in the presence of a base, e.g. pyridine or a tertiary amine, at a low temperature, e.g. at a temperature of 0 C to 300 C. Compounds of general formula XXXIX may be prepared by treating compounds of general formula XXXVII I by methods known per se for the removal of the trimethylsilyl group, for example by treatment with an acid: it is preferable not to use a strong acid in order to avoid the risk of the removal of the group R8. Compounds of general formula XXXIX may be converted to compounds of general formula XXXV under mild and neutral conditions, e.g. with chromium trioxide-pyridine complex or Jones' reagent at a moderately low temperature.
Compounds of general formula XXXVI may be prepared by the methods described in Japanese Patent Publication No. 49-102646 from compounds of formula XX which may be represented by the series of reactions depicted schematically below in Scheme E, wherein the various symbols are as hereinbefore defined.
SCHEME E
Compounds of general formula XL may be prepared by hydrolysis under alkaline conditions of compounds of formula XX, for example using potassium hydroxide in methanol. Compounds of formula XLI may be obtained by the acetylation of compounds of formula XL under mild conditions and may be converted to compounds of general formula XLII by reaction with a dihydropyran, dihydrofuran or ethyl vinyl ether in an inert organic solvent, e.g. methylene chloride, in the presence of a condensing agent, e.g. p-toluenesulphonic acid.
Compounds of general formula XLIII may be prepared by reducing compounds of general formula XLII with diisobutylaluminium hydride in toluene for about 15 minutes at -600C. Dimsyl anion, previously prepared from sodium hydride and dimethyl sulphoxide, is reacted with (4-carboxybutyl)triphenylphosphonium bromide to form (4-carboxybutylidene)triphenylphosphorane. To that compound is added a compound of general formula XLIII and the mixture in dimethyl sulphoxide is made to react for 2 hours at room temperature to yield compounds of general formula XLIV. The acids of general formula XLIV are then esterified to compounds of general formula XXXVIA using a method heretofore mentioned for the esterification of compounds of general formula XVIA to those of general formula formula XVIB. If desired, compounds of general formula XXXVIA may be reduced to give compounds of general formula XXXVI B by means heretofore mentioned for the reduction of compounds of general formulae XVIA and XVIB to those of general formula XVIC.
If desired, compounds of general formula Xl II, wherein the various symbols are as hereinbefore defined, may be prepared by the series of reactions depicted in
Scheme A (XVIe XVIIe XVIIIo XIXo XIe XIII) but replacing the compounds of general formula XVI by compounds of the general formula:
wherein R'7 represents a 2-tetrahydrofuranyl group or a l-ethoxyethyl group or a 2tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group and the other symbols are as hereinbefore defined.
Compounds of general formula XLV may be prepared from compounds of general formula XVI by reaction with a dihydropyran, dihydrofuran or ethyl vinyl ether in an inert organic solvent, e.g. methylene chloride, in the presence of a condensing agent, e.g. p-toluenesulphonic acid.
Compounds of general formula XXXIII, wherein R4 is other than a grouping of formula VIII, and the other symbols are as hereinbefore defined, may also be prepared from compounds of general formula XXXV by the series of reactions depicted schematically below in Scheme F, wherein R3 is as hereinbefore defined and R4' represents a cycloalkyl group containing from 5 to 7 carbon atoms or a grouping of formula VII, or R3 and R4' together represent a straight- or branchedchain alkyl group containing from I to 10 carbon atoms, and the other symbols are as hereinbefore defined.
SCHEME F
Compounds of general formula XLVI, wherein the various symbols are as hereinbefore defined, may be prepared from compounds of general formula XXXV by reaction with formylmethylenetriphenylphosphorane in an inert organic solvent, e.g. benzene, at about 70"C for several hours, e.g. 20 hours.
Compounds of general formula XXXIII, wherein R2 represents a hydrogen atom and the other symbols are as hereinbefore defined [hereinbefore depicted in formula XXXIIIA], may be prepared from compounds of general formula XLVI by the Grignard reaction with a Grignard reagent of the general formula HalMgR3--R4' (wherein Hal represents a halogen atom and the other symbols are as hereinbefore defined) in an inert organic solvent, e.g. diethyl ether, at a low temperature, e.g. at OOC, followed by hydrolysis of the resulting organomagnesium compounds, for example by treatment with water or an aqueous solution of ammonium chloride or an acid, e.g. hydrochloric acid or oxalic acid, to give a mixture of the 1Sa- and 15p-hydroxy epimers of compounds of general formula
XXXIIIA. It is sometimes possible to separate the 15a-hydroxy epimer from the 15p-hydroxy epimer by column chromatography on silica gel.
If desired, compounds of general formula XXXIII wherein R2 represents a methyl group and the other symbols are as hereinbefore defined, i.e. compounds of general formula XXXIIIB, may be prepared from compounds of general formula
XXXIIIA by oxidation with a chromic acid solution (e.g. obtained from chromium trioxide, manganese sulphate and sulphuric acid in water) or Jones' reagent, and then by the Grignard reaction of the resulting compound of general formula
XXXIV with a methylmagnesium halide followed by hydrolysis of the organomagnesium compound so formed.
Compounds of general formula XVI, wherein Rg represents a 2tetrahydrofuranyl group or a l-ethoxyethyl group or a 2-tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group and the other symbols are as hereinbefore defined, may also be prepared from compounds of general formula
XXXIII by the sequence of reactions hereinafter depicted schematically in Scheme
G, wherein the various symbols are as hereinbefore defined.
SCHEME G
The conversion of compounds of general formula XXXIII to those of general formula XLVII may be carried out by means heretofore mentioned for the conversion of compounds of general formula XXV to those of general formula
XXVI.
The conversion of compounds of general formula XLVII to those of general formula XVID may be carried out by means heretofore mentioned for the conversion of compounds of general formula XXXIII to those of general formula
XVI.
Compounds of general formula XLVI, wherein Y represents cis-vinylene and the other symbols are as hereinbefore defined, may also be prepared by the sequences of reactions hereinafter depicted schematically in Scheme H, wherein
RIB represents a straight- or branched-chain alkyl group containing from I to 4 carbon atoms and the other symbols are as hereinbefore defined.
SCHEME H
Referring to Scheme H, compounds of general formula XLII may be converted to compounds of general formula XLVIII by deacetylation with anhydrous potassium carbonate in absolute methanol.
Compounds of general formula XLVIII may be converted to compounds of general formula XLIX by oxidation under mild conditions, e.g. with Collin's reagent at a moderately low temperature.
Compounds of general formula XLIX may be transformed stereospecifically to trans-a,-unsaturated esters of general formula L by reaction with the sodio derivatives of the general formula:
(wherein Rla is as hereinbefore defined and R'9 represents an alkyl group containing from I to 4 carbon atoms) in an inert organic solvent, e.g.
tetrahydrofuran or 1,2-dimethoxyethane, at a temperature of O" to 300C for 2 hours, in a high yield, e.g. 70% to 90%.
Compounds of general formula L may also be prepared from compounds of general formula XXI via formula LI and formula LII. The conversion of compounds of formula XXI to those of general formula LI may be carried out by means heretofore mentioned for the conversion of compounds of general formula
XLIX to those of general formula L. Compounds of general formula LI may be converted to compounds of general formula L by selective deacetylation with an equimolar amount of anhydrous potassium carbonate in absolute methanol and then etherification with a dihydropyran, or dihydrofuran or ethyl vinyl ether in an inert organic solvent, e.g. methylene chloride, in the presence of a condensing agent, e.g. --toluenesulphonic acid.
Compounds of general formula L may be converted quantitatively to compounds of general formula LIII by reduction with more than three molar equivalents of diisobutylaluminium hydride in an inert organic solvent, e.g.
toluene, n-pentane or n-hexane, at a low temperature, e.g. -780C to --200C.
The conversion of compounds of general formula LIII to those of general formula LIV may be carried out by means heretofore mentioned for the conversion of compounds of general formula XXVII to those of general formula XVI A.
The esterification of compounds of general formula LIV to those of general formula LV may be carried out by means heretofore mentioned for the reaction of compounds of general formula XVIA to those of general formula XVI B.
Compounds of general formula LV may be converted to compounds of general formula LVI by reaction with trimethylchlorosilane in an inert organic solvent, e.g.
methylene chloride, in the presence of a base, e.g. pyridine or a tertiary amine, at a low temperature, e.g. at a temperature of -30" to OOC, then reacting the resulting trimethylsilyl ether with an appropriate acyl halide or acid anhydride in an inert organic solvent, e.g. methylene chloride, in the presence of a base, e.g. pyridine or a tertiary amine, at a low temperature, e.g. at a temperature of 0 to 300 C, and treating the resulting acyl ether by methods known per se for the removal of the trimethylsilyl group, for example by treatment with an acid; it is preferable not to use a strong acid in order to avoid the risk of the removal of the group RB.
Compounds of general formula LVI may be converted to compounds of general formula XLVIA by oxidation with manganese dioxide, for example in an inert organic solvent, e.g. methylene chloride, at laboratory temperature, which oxidizes an allylic alcohol group selectively.
Compounds of general formula XLVIA may be prepared from compounds of general formula LV by oxidation with manganese dioxide in an inert organic solvent, e.g. methylene chloride, at laboratory temperature, and then acylation of the resulting compound of general formula LVII.
According to a further feature of the present invention, compounds of general formula IXA are prepared from compounds of general formula XXXVI by the series of reactions depicted schematically below in Scheme I, wherein R20 represents the benzoyl or acetyl group, and the other symbols are as hereinbefore defined.
SCHEME I
SCHEME I (CONTINUED)
Compounds of general formula LIX may be prepared from compounds of general formula XXXVI by reaction (I) with benzoyl chloride in an inert organic solvent, e.g. methylene chloride, in the presence of a base, e.g. pyridine or a tertiary amine, at a moderately low temperature, preferably at -200 to -25 C, or (2) with acetyl chloride or acetic anhydride in an inert organic solvent, e.g.
methylene chloride, in the presence of a base, e.g. pyridine or a tertiary amine, at a low temperature of 0 to 300 C, and may be converted to compounds of general formula LX by means heretofore mentioned for the conversion of compounds of general formula XXV to those of general formula XXVI.
Compounds of general formula LXI may be prepared from compounds of general formula LX by means heretofore mentioned for the conversion of compounds of general formula XXXIII to those of general formula XVI.
The series of reactions LXI < LXIII (via XII) may be effected as hereinbefore described for the series of reactions XVI e XI (via XVII, XVIII and
XIX) in Scheme A.
The series of reactions LXIII - LXVI (via LXIV and LXV) may be effected as hereinbefore described for the series of reactions XX -t XXIVA or XXIVB (via XXI and XXIII) in Scheme B.
Compounds of general formula LXVII may be prepared from compounds of general formula LXVI by means heretofore mentioned for the conversion of compounds of general formula XI to those of general formula XA, and may be converted to compounds of general formula IXA by means heretofore mentioned for the conversion of compounds of general formula X to those of general formula
IX.
Compounds of general formula IXA may also be prepared from compounds of general formula LXVI via compounds of general formula XI II.
The conversion of compounds of general formula LXVI to those of general formula XIII may be carried out by means heretofore mentioned for the conversion of compounds of general formula X to those of general formula IX.
According to a further feature of the present invention, compounds of general formula IXA are also prepared from compounds of general formula XIII by the series of reactions depicted schematically below in Scheme J. wherein the various symbols are as hereinbefore defined.
SCHEME J
The conversion of compounds of general formula XIII to those of general formula LXVIII may be carried out by means heretofore mentioned for the conversion of compounds of general formula XXV to those of general formula
XXVI.
The series of reactions LXVIII IXA (via LXIX) may be effected as hereinbefore described for the series of reactions Xl < IXA (via XA) in Scheme A.
According to a further feature of the present invention, compounds of general formula VI, wherein X represents ethylene or trans-vinylene, R1 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms, the double bonds between C3-C4 and C13-C14 are trans, and the other symbols are as hereinbefore defined, i.e. compounds of the general formula:
(wherein W represents ethylene or trans-vinylene, and the other symbols are as hereinbefore defined) are prepared from compounds of general formula IXA, wherein the various symbols are as hereinbefore defined, by the series of reactions depicted schematically below in Scheme K, wherein the various symbols are as hereinbefore defined.
SCHEME K
The conversion of compounds of general formula IXA to those of general formula LXIX may be carried out by means heretofore mentioned for the conversion of compounds of general formula XXV to those of general formula
XXVI.
The photoisomerization of compounds of general formula LXIX to those of general formula LXXI may be carried out by irradiation (i) when Y represents cisvinylene, with diffuse laboratory light in carbon tetrachloride in the presence of iodine at room temperature [cf. J. Amer. Chem. Soc. 75, 3430 (1953)], or (ii) when
Y represents ethylene, with light from a high pressure mercury lamp in an inert organic solvent, e.g. benzenemethanol mixture, in the presence of diphenyl sulphide or diphenyl disulphide at room temperature.
The conversion of compounds of general formula LXXI to those of general formula LXXA may be carried out by means heretofore mentioned for the conversion of compounds of general formula X to those of general formula IX.
The series of reactions LXXA < LXXB (via LXXII and LXXIII) may be effected as hereinbefore described for the series of reactions IXA < IXB (via XV and XIV in Scheme A.
The present invention accordingly provides a process for the preparation of prostaglandin analogues of general formula VI wherein Z represents
R' represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms, and the other symbols are as hereinbefore defined, i.e. compounds of the general formula:
(wherein the various symbols are as hereinbefore defined and (1) the double bond between C3-C4 is trans or cis, or trans and cis, when X is cis-vinylene or ethylene and (2) the double bond between C2-C4 is trans, when X is trans-vinylene and the double bond between C12-C14 is trans) which comprises hydrolysing a compound of the general formula:
wherein the various symbols are as hereinbefore defined, the double bond between C3-C4 is as hereinbefore specified in relation to compounds of general formula
VIA and the double bond between C13-C14 is trans.
The conversion of compounds of general formula LXIXA to those of formula
VIA may be effected as hereinbefore described for the conversion of compounds of general formula XA to those of general formula IXA.
It is to be understood that in formulae VIB and XIVA below the double bond depicted in the grouping
attached to the cyclopentane ring is as specified above in relation to compounds of general formula VIA, and the double bond between C13-C14 is trans.
The invention accordingly also provides a process for the preparation of prostaglandin analogues of general formula VI wherein R1 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from I to 4 carbon atoms and Z represents
i.e. compounds of the general formula:
(wherein the various symbols are as hereinbefore defined) which comprises hydrolysing the silyloxy groups of a compound of the general formula:
(wherein the various symbols are as hereinbefore defined) to hydroxy groups under extremely mild acidic conditions.
The conversion of compounds of general formula XIVA to those of formula
VIB may be effected as hereinbefore described for the conversion of compounds of general formula XIV to those of general formula IXB.
Compounds of general formulae X, LXVII, LXIXA and XIVA are new compounds and, with the exclusion of compounds of general formula X wherein Z represents C=O, R7 and R2 represent hydrogen atoms, R3 and R4 together represent n-pentyl and the double bond between C2-C4 is trans, and of compounds of general formula XIVA wherein X represents cis-vinylene or ethylene, R7 and R2 represent hydrogen atoms, R3 and R4 together represent n-pentyl and the double bond between C2-C4 is trans, constitute a further feature of the present invention.
According to a further feature of the present invention, the compounds of general formula VI, wherein R1 represents a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms and the other symbols are as hereinbefore defined, are prepared by esterification of the corresponding acids of general formula VI, wherein R1 represents a hydrogen atom and the other symbols are as hereinbefore defined, by methods known per se, for example by reaction with (i) appropriate diazoalkanes in an inert organic solvent, e.g. diethyl ether, at a temperature of -10" to 250C, preferably at OOC, (ii) appropriate alc sufficiently insoluble in the reaction medium, by filtration, if necessary atter removal of part of the solvent.
Cyclodextrin clathrates of the prostaglandin analogues of genral formula VI may be prepared by dissolving the cyclodextrin in water or an organic solvent which is miscible with water and adding to the solution the prostaglandin analogue in a water-miscible organic solvent. The mixture is then heated and the desired cyclodextrin clathrate product isolated by concentrating the mixture under reduced pressure or by cooling and separating the product by filtration or decantation. The ratio of organic solvent to water may be varied according to the solubilities of the starting materials and products. Preferably the temperature is not allowed to exceed 70 C during the preparation of the cyclodextrin clathrates. α,ss- or y-Cyclodextrins or mixtures thereof may be used in the preparation of the cyclodextrin clathrates. Conversion into their cyclodextrin clathrates serves to increase the stability of the prostaglandin analogues.
The prostaglandin analogues of general formula VI and their cyclodextrin clathrates and, when R1 in formula VI represents a hydrogen atom, their non-toxic salts possess the valuable pharmacological properties typical of the prostaglandins in a selective fashion, in particular stimulatory activity on uterine contraction and abortifacient, luteolytic and antinidatory activity, and are useful in the termination of pregnancy and induction of labour in pregnant female mammals and in the treatment of impaired fertility, in the control of oestrus, contraception and menstrual regulation in female mammals. For example, in standard laboratory tests, (i) 17-phenyl-18,19,20-trinor-trans and cis-A3-PGF2, methyl ester, 16-(3trifluoromethylphenoxy)- 17,18,19,20-tetranor-trans and cis-A3-PGF2a methyl ester, 16-(3-chlorophenoxy)- 17,18,1 9,20-tetranor-trans and cis-53-PGF2 < r methyl ester, 16-phenoxy-17,18,19,20-tetranor-trans and cis-A3-pGF2 < methyl ester, 16-(3chlorophenoxy)-17, 17,18,19,20-tetranor-cis-#3-PGF2α methyl ester, 16-(3 chlorophenoxy)- 17,18,1 9,20-tetranor-trans-α2-PGF2α methyl ester, 16-phenoxy 17,18,19,20-tetranor-cis-α3-PGF2α, methyl ester, 16-phenoxy- 17,18,19,20-tetranor trans-α3-PGF2α methyl ester, 16-(4-chlorophenoxy)- 17,18,1 9,20-tetranor-trans and cis-A3-PGF2 < , methyl ester, methyl 9α,11α,15α-trihydroxy-16-phenoxy-17,18,19,20- tetranorprosta-trans-3,trans-5,trans-13-trienoate, methyl 9α,11α,15α-trihydroxy-16- (3 - chlorophenoxy) - 17,18,19,20-tetranorprosta- trans - 3,trans - 5,trans - 13 -trienoate and 16-phenoxy-17,18,19,20-tetranor-trans and cis-A3-POF1a methyl ester inhibit implantation in the pregnant female rat when administered subcutaneously on the 3rd, 4th and 5th days of pregnancy at the daily doses of 200, 50, 5, 5, 10,5, 10,5, 10, 20, 20 and 100yg/kg animal body weight, respectively; (ii) 16-(3trifluoromethylphenoxy)-17,18,19,20-tetranor-trans and cis-53-PGF2 < , methyl ester, 16-(3-chlorophenoxy)-17,18,19,20-tetranor-trans and cis-#3-PGF2α, methyl ester and 16-phenoxy-17,18,19,20-tetranor-trans and cis-A3-PGF2, methyl ester produce an abortifacient effect in the pregnant female rat when administered intraperitoneally on the 17th day of pregnancy at the daily doses of 10.0, 2.0 and 1.0yg/kg animal body weight, respectively; (iii) in tests for luteolytic effect [Rats are hysterectomized on the 5th day of gestation (day 0= sperm confirmation). The compound under test is administered subcutaneously from the 2nd day following the hysterectomy. The luteal period is observed by the vaginal smear test. The compound is administered each day until the first oestrus begins. The compound is regarded as effective if the first oestrus begins within 5 days.], 16-(3-trifluoromethylphenoxy)-17,18,19,20-tetranor-trans and cis-A2-POF2a methyl ester, 16-(3chlorophenoxy)-17,18,19,20-tetranor-trans and cis-A3-pGF2 methyl ester and 16phenoxy- 17,18,19,20-tetranor-trans and cis-A3-PGF2 < , methyl ester produce 66.7%, 60.0% and 85.7% luteolytic effect, respectively, at the daily doses of 0.5, 0.2 and 0.2 ug/kg animal body weight, respectively, and (iv) 17-phenyl-18,19,20-trinor-trans and cis-A3-POF2a methyl ester, 16-(3-trifluoromethylphenoxy)-17,18,19,20- tetranor-trans and cis-A3-PGF2, methyl ester, 16-(3-chlorophenoxy)- 17,18,19,20- tetranor-trans and cis-å3-PGF2a methyl ester, 16-phenoxy-17,18,19,20-tetranortrans and cis-A3-PGF2 methyl ester, trans and cis-#3-PGF1α, 16-(4-chlorophenoxy) 17,18,19,20-tetranor-trans and cis-A3-PGF2a methyl ester, 16,16-dimethyl-trans and cis-A3-PGE, methyl ester, methyl 9α,11α,15α-trihydroxy-16-phenoxy-17,18,19,20- tetranorprosta-trans-3 ,trans-5 ,trans-13-trienoate and methyl 9α, 11α, 15α-trihydroxy- 16 - (3 - chlorophenoxy) - 17,18,19,20 - tetranorprosta - trans - 3,trans - 5,trans 13-trienoate stimulate uterine contraction in the pregnant female rat when administered intravenously on the 20th day of gestation at the doses of 5-1 0, 2, 2, 1--2, 200, 2-5, 0.2, 2 and 2g1l:g animal body weight, respectively.
The following Reference Examples and Examples illustrate the preparation of
new prostaglandin analogues of the present invention. In them, 'IR', 'NMR' and
'TLC' represent respectively 'Infrared absorption spectrum', 'Nuclear magnetic
resonance spectrum' and 'Thin layer chromatography'. Where solvent ratios are
specified in chromatographic separations, the ratios are by volume.
EXAMPLE 1.
Methyl 9a, 11 a, 1 Sa-trihydroxy- I 6-(3-trifluoromethylphenoxy)- 17,18,1 9,20-tetranor- prosta-trans and cis-3,cis-5,trans- 1 3-trienoate [or 16-(3-trifluoromethylphenoxy)
17,18,19,20-tetranor-trans and cisA3-POF2a methyl ester]
To a solution of 160 mg of methyl 9a, l l ce,15-trihydroxy- 16-(3-trifluoro- methylphenoxy)- 17,18,1 9,20-tetranorprosta-trans-2,cis-5,trans- 1313-trienoate in 4 ml of methanol there were added 250 mg of anhydrous potassium carbonate and the mixture was stirred at room temperature for one hour. The reaction mixture was then poured into an aqueous solution of ammonium chloride and extracted with
ethyl acetate. The extract was washed with an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The
residue was purified by column chromatography on silica gel using a mixture of
benzene and ethyl acetate (2:1) as eluent to give 110mg of the title compound
having the following physical characteristics: TLC (developing solvent, ethyl acetate): Rf = 0.16;
IR (liquid film): v; 3400, 1740, 1600, 1490, 1450, 1340, 800 cm-l; NMR (CDCI3 solution): ; 7.507.00 (4H, m), 6.15-5.30 (6H, m), 4.65--4.40 ;(lH, m), 4.27-3.80 (4H, m), 3.66 and 3.67 (3H, each s), 3.19 and 3.11 (2H, each d).
EXAMPLE 2.
Methyl 9a,11 a,15a-trihydroxy- 16-(3-chlorophenoxy)- 17,18, 19,20-tetranorprostatrans and cis-3,cis-5,trans- 1 3-trienoate [or 16-(3-chlorophenoxy)- 17,18,19,20-tetranor-trans and cis-å3-PGF2, methyl ester]
To a solution of 100 mg of methyl 9α,11α,15α-trihydroxy-16-(3-chloro- phenoxy)-17,18,19,20-tetranorprosta-trans-2,cis-5,trans-13-trienoate in 2 ml of methanol there were added 79 mg of anhydrous potassium carbonate and the mixture was stirred at 0 C for 2 hours. The reaction mixture was then poured into an aqueous solution of ammonium chloride and extracted with ethyl acetate. The extract was washed with an aqueous solution of sodium chloride, dried over
magnesium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of cyclohexane and ethyl acetate (1:1) as eluent to give 75 mg of the title compound having the following physical characteristics: TLC (developing solvent, chloroform-tetrahydrofuran-acetic acid = 10:2:1): Rf = 0.21;
IR (liquid film): v; 3400, 2950, 1740, 1600, 1580, 1480, 1435, 980 cm~l; NMR (CDCl2 solution): b; 7.4--6.7 (4H, m), 6.7-5.2 (6H, m), 4.6--4.3 (1H, m), 4.34.05 (1H, m), 4.05-3.77 (3H, m), 3.66 and 3.67 (3H, each s), 3.11 and 3.19 (2H, each d); ultraviolet absorption (ethanol solution): Amax = 2.30 m4.
REFERENCE EXAMPLE 1.
Methyl 9a-acetoxy- 11 a-(2-tetrahydropyranyloxy)- 15α-hydroxy-17-phenyl-18,19,20- trinorprosta-cis-5,trans- 13-dienoate
To 20 ml of diethyl ether there were added 500 mg of magnesium and a small
amount of iodine. The mixture was refluxed, 2.03 ml of l-bromo-2-phenylethane were added dropwise to the mixture and the mixture was stirred for one hour with
reflux.
To a solution of 2.08 g of la-acetoxy-2a-(6-methoxycarbonylhex-cis-2-enyl)- 3ss-(2-formyl-trans-vinyl)-4a-(2-tetrahydropyranyloxy)cyclopentane (prepared as described in Japanese Patent Publication No. 50-137961 or Belgian Patent
Specification No. 827803) in 40 ml of diethyl ether were added dropwise 17 ml of the ethereal solution obtained above at 0 C and the mixture stirred at 0 C for one hour. The reaction mixture was poured into an aqueous solution of ammonium chloride, extracted with ethyl acetate, washed with water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (4:1) as eluent to give 770 mg of the title compound, 840 mg of its 15ss-hydroxy epimer and 570 mg of their mixture. The title compound showed the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.38, (15p-hydroxy epimer, Rf = 0.48);
IR (liquid film): v; 3450, 1740, 1610, 1490, 1250, 980, 760 cm-l; NMR (CDCI3 solution): b; 7.35 (5H, broad s), 5.85-5.00 (5H, m), 4.854.55 (1H, m), 3.70 (3H, s), 2.08 (3H, s).
REFERENCE EXAMPLE 2.
Methyl 9a-acetoxy- 11 a, 1 5a-bis(2-tetrahydropyranyloxy)- 17-phenyl-18,1 9,20-tri- norprosta-cis-5,trans- 13-dienoate
To a solution of 1.25 g of methyl 9a-acetoxy-l la-(2-tetrahydropyranyloxy)- I 5a-hydroxy- I 7-phenyl- 18,1 9,20-trinorprosta-cis-5,trans- 1 3-dienoate (prepared as described in Reference Example I) in 20 ml of methylene chloride were added 0.52 ml of 2,3-dihydropyran and a catalytic amount ofp-toluenesulphonic acid. The mixture was stirred at room temperature for 30 minutes, and then neutralized with an aqueous solution of sodium bicarbonate. The reaction mixture was diluted with ethyl acetate, washed with water and an aqueous solution of sodium chloride, dried over sodium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (9:1) as eluent to give 1.37g of the title compound having the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.73 IR (liquid film): v; 1740, 1500, 1250, 1030, 980, 760 cm-l; NMR (CDCI3 solution): ô; 7.32 (5H, broad s), 5.85-5.00 (5H, m), 4.954.55 (2H, m), 3.68 (3H, s), 2.07 (3H, s).
REFERENCE EXAMPLE 3.
Methyl 9a-hydroxy- II a, I 5a-bis(2-tetrahydropyranyloxy)- 17-phenyl-18, 19,20-tri- norprosta-cis-5 ,trans- I 3-dienoate
To a solution of 1.36 g of methyl 9a-acetoxy-l Ia, I 5a-bis(2-tetrahydropyranyl- oxy)- 1 7-phenyl- 18,1 9,20-trinorprosta-cis-5,trans- 13-dienoate (prepared as described in Reference Example 2) in 18 ml of methanol were added 460 mg of anhydrous potassium carbonate, and the mixture was stirred at 400C for 2.5 hours.
The reaction mixture was then neutralized with IN hydrochloric acid, diluted with ethyl acetate, washed with an aqueous solution of sodium bicarbonate and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure to give 1.12g of the title compound having the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.47; IR (liquid film): v; 3450, 1740, 1500, 1440, 1030, 980, 760 cm-l; NMR (CDCI3 solution): b; 7.40 (5H, s), 5.905.35 (4H, m), 4.954.65 (2H, m), 3.72 (3H, s).
REFERENCE EXAMPLE 4.
Methyl 2-phenylseleno-cu- hydroxy-lla,l5cr- bis(2 -tetrahydropyranyloxy)- 17 phenyl- 18,1 9,20-trinorprosta-cis-5,trans- 1 3-dienoate
To a solution of 0.67 ml of diisopropylamine in 15 ml of tetrahydrofuran were added dropwise 3.3 ml of a 1.4M solution of n-butyllithium in n-hexane at -78 C, and the mixture was stirred at that temperature for 15 minutes to give a lithium diisopropylamide solution. To the lithium diisopropylamide solution was added dropwise a solution of 1.1 g of methyl 9a-hydroxy-l la,l5a-bis(2-tetrahydro- pyranyloxy)- I 7-phenyl- 18,1 9,20-trinorprosta-cis-5,trans- 13-dienoate (prepared as described in Reference Example 3) in 2 ml of tetrahydrofuran at -780C, and the mixture was stirred at the same temperature for 20 minutes. To the reaction mixture was added dropwise a solution of 930 mg of diphenyl diselenide in 3 ml of tetrahydrofuran at -780C, and stirring was continued for one hour. The reaction mixture was then poured into an aqueous solution of ammonium chloride, and extracted with ethyl acetate. The extract was washed with water, 1N hydrochloric acid, an aqueous solution of sodium bicarbonate and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (5:1) as eluent to give 1.13g of the title compound having the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.56;
IR (liquid film): v; 3450, 1735, 1580, 1440, 1030, 980, 750 cm-l; NMR (CDCI3 solution): α; 7.90-7.00 (10H, m), 5.75-5.15 (4H, m), 4.904.55 (2H, m), 3.62 (3H, s).
REFERENCE EXAMPLE 5.
Methyl 9α-hydroxy-11α,15α-bis(2-tetrahydropyranyloxy)- 17-phenyl-18,19,20-tri- norprosta-trans-2,cis-5 ,trans- 1 3-trienoate
To a solution of 1.1 g of methyl 2-phenylseleno-9α-hydroxy-11α,15α-bis(2- tetrahydropyranyloxy)- 17-phenyl- 18,19,20-trinorprosta-cis-5,trans-l 3-dienoate (prepared as described in Reference Example 4) in 15 ml. of a mixture of ethyl acetate and tetrahydrofuran (2:1) were added 0.8 ml of 30% hydrogen peroxide, and the mixture was stirred at 300C for 40 minutes. The reaction mixture was poured into water, washed with an aqueous solution of sodium carbonate, water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure to give 960 mg of the title compound having the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.47;
IR (liquid film): v; 3450, 1735, 1650, 1500, 1030, 980, 760 cm-1;
NMR (CDCI3 solution): 6; 7.50--6.75 (6H, m), 6.10--5.30 (5H, m), 4.90--4.60 (2H, m), 3.72 (3H, s).
REFERENCE EXAMPLE 6.
Methyl 9a, II a, 1 5a-trihydroxy- 1 17-phenyl-18,19,20-trinorprosta-trans-2,cis-5,trans- 13-trienoate [or 17-phenyl-18,19,20-trinor-trans-A2-PGF2,t methyl ester]
To a solution of 250 mg of methyl 9a-hydroxy-1 1a,15a-bis(2-tetrahydro- pyranyloxy)- 17-phenyl-18,19,20-trinorprosta-trans-2,cis-5,trans- 13-trienoate (prepared as described in Reference Example 5) in 4 ml of tetrahydrofuran were added 1.5 ml of 1N hydrochloric acid, and the mixture was stirred at 400C for one hour.
The reaction mixture was then poured into water, extracted with ethyl acetate, and the extract was washed with water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of ethyl acetate and cyclohexane (1:1) as eluent to give 130 mg of the title compound having the following physical characteristics: TLC (developing solvent, ethyl acetate): Rf = 0.18;
IR (liquid film): v; 3400, 1730, 1660, 1500, 1050, 980, 750 cm-l;
NMR (CDCl2 solution): o; 5.70--5.20 (4H, m), 4.20--3.80 (3H, m), 3.68 (3H, s).
EXAMPLE 3.
Methyl 9α,11α,15α-trihydroxy-17-phenyl- 18,19,20-trinorprosta-trans and cis-3,cis 5,trans- 1 3-trienoate [or 17-phenyl-18,19,20-trinor-trans and cis-A3-PGF2l methyl ester]
By proceeding as described in Example 1 but replacing the methyl 9a,l la,15a- trihydroxy - 16 - (3 - trifluoromethylphenoxy) - 17,18,19,20 - tetranorprosta trans-2,cis-5,trans- 13-trienoate by 50 mg of methyl 9a, 11 a, 1 Sa-trihydroxy- 17phenyl-18,19,20-trinorprosta-trans-2,cis-5,trans- 13-trienoate (prepared as described in Reference Example 6) dissolved in 1.5 ml of methanol and utilizing 85 mg of anhydrous potassium carbonate there were obtained 33 mg of the title compound having the following physical characteristics: TLC (developing solvent, ethyl acetate): Rf = 0.18;
IR (liquid film): v; 3400, 1740, 1640, 1500, 1440, 1250, 980, 750 cm-1;
NMR (CDCI2 solution): 6; 7.4-7.00 (5H, m), 6.10--5.30 (6H, m), 4.20--3.80 (3H, m), 3.64 and 3.65 (3H, each s), 3.05 and 3.16 (2H, each d).
EXAMPLE 4.
Methyl 9a, 11 a, 1 Sa-trihydroxy- 16-(3-trifluoromethylphenoxy)- 17,18,19,20-tetra- norprosta-trans and cis-3 ,cis-5,trans- 1 3-trienoate [or 16-(3-trifluoromethylphenoxy)- 17,18,19,20-tetranor-trans and cis-A3-PGF2 < , methyl ester
Under an atmosphere of nitrogen, 0.27 m! of a 1.4M solution of n-butyllithlum in n-hexane was added dropwise to a solution of 37.7 mg of diisopropylamine in
I ml of tetrahydrofuran at -200C and the mixture was stirred at the same temperature for 15 minutes to give lithium diisopropylamide. To the lithium diisopropylamide solution was added a solution of 73.2 mg of hexamethylphosphoramide in I ml of tetrahydrofuran at -700C and the mixture was stirred at the same tem perature for 30 minutes. To the resulting solution was added dropwise a solution of 40 mg of methyl 9α,11α,l5α-trihydroxy-16-(3-trifluoromethylphenoxy)- 17,18,19,20-tetranorprosta-trans-2,cis-5,trans-13-trienoate in 2 ml of tetrahydrofuran at -70 C, and the mixture was stirred at the same temperature for 2 hours and then concentrated under reduced pressure. The residue was diluted with 100 ml of diethyl ether, washed with water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (2:1) as eluent to give 32 mg of the title compound having the same physical characteristics as those of the product of
Example 1.
EXAMPLE 5.
Methyl 9a, II a, I Sa-trihydroxy- 16-phenoxy-17,18,19,20-tetranorprosta-trans and cis-3,cis-5,trans- I 3-trienoate [or I 6-phenoxy- 17,18,1 9,20-tetranor-trans and cis 53-PGF2n methyl ester]
By proceeding as described in Example 2, but replacing the methyl 9a, 11 al 5a- trihydroxy - 16 - (3 - chlorophenoxy) - 17,18,19,20 - tetranorprosta - trans - 2,cis - 5, trans-13-trienoate by 165 mg of methyl 9α,11α,l5α-trihydroxy-16-phenoxy- 17,18,19,20-tetranorprosta-trans-2-cis-5,trans-l3-trienoate dissolved in 3 ml of methanol and utilizing 142 mg of potassium carbonate, there were obtained 141 mg of the title compound having the following physical characteristics: TLC (developing solvent, ethyl acetate): Rf = 0.28; IR (liquid film): v; 3400, 2950, 1730, 1600, 1590, 1490, 980 cm-1; NMR (CDCI3 + D2O solution): oo 7.4--6.7 (5H, m), 6.7-5.2 (6H, m), 4.74.3 (1H, m), 4.3-3.76 (4H, m), 3.67 and 3.66 (3H, each s), 3.3-2.9 (5H, m); ultraviolet absorption (ethanol solution): Amax[Emax]; 205117550], 233[27180], 234[23640], 271[1896], 277[1543] m,u.
EXAMPLE 6.
Methyl 9a, 11 a, 15α-trihydroxy-l6-(4-chlorophenoxy)- 17,18,1 9,20-tetranorprostatrans and cis-3,cis-5,trans-13-trienoate [or I 6-(4-chlorophenoxy)- 17,18,19,20-tetranor-trans and cis-53-PGF2a methyl ester]
By proceeding as described in Example 2 but replacing the methyl 9α,11α,l5α- trihydroxy - 16 - (3 - chlorophenoxy) - 17,18,19,20 - tetranorprosta - trans - 2,cis 5,trans-13-trienoate by 32 mg of methyl 9α,11α,15α-trihydroxy-16-(4-chloro- phenoxy)- 17,18,19,20 - tetranorprosta-trans-2,cis-5,trans- 13-trienoate dissolved in 2 ml of methanol and utilizing 30 mg of potassium carbonate, there were obtained 23 mg of the title compound having the following physical characteristics: TLC (developing solvent, chloroform-tetrahydrofuran-acetic acid = 10:2:1):
Rf = 0.22;
NMR (CDCI3 solution): #; 7.40--7.05 (2H, m), 6.95-6.65 (2H, m), 6.63-5.10 (6H, m), 4.644.28 (lH, m), 4.254.02 (IH, m), 4.02-3.77 (3H, m), 3.67 and 3.66 (3H, each s), 3.19 and 3.11 (2H, each d).
EXAMPLE 7.
Methyl 9a, II a, 1 Sa-trihydroxy- I 6-(3-chlorophenoxy)- 17,18,1 9,20-tetranorprostatrans-3,cis-5,trans- 1 3-trienoate [or 1 6-(3-chlorophenoxy)- 17,18,1 9,20-tetranor-trans A2POF2a methyl ester] and methyl 9α,11α,15α-trihydroxy-16-(3-chlorophenoxy)- 17,18,1 9,20-tetranorprosta-cis-3,cis-5,trans- I 3-trienoate [or 16-(3-chlorophenoxy) 17,18,19,20-tetranor-cis-53-PGF2a methyl ester]
110 mg of methyl 9α, 11α, 15α-trihydroxy- 16-(3-chlorophenoxy)- 17,18,19,20- tetranorprosta-trans and cis-3 ,cis-5 ,trans- 13-trienoate (prepared as described in
Example 2) were separated by thin layer chromatography on silica gel pre-treated with silver nitrate developing two times with a mixture of chloroform and methanol (first ratio 10:1, second ratio 5:1) as developing solvent to give 13 mg of the trans-A3compound, 13 mg of the cis-A2-compound, and 35 mg of the starting material. The products showed the following physical characteristics: (1) 6-(3-chlorophenoxy)- 17,18,19,20-tetranor-trans-#3-PGF2α, methyl ester
TLC (developing solvent, chloroform-methanol = 5:1, using a silica gel plate pretreated with AgNO3, twice development): Rf = 0.51;
NMR (CDC13 solution): S; 7.25-6.68 (4H, m), 6.68-5.20 (6H, m), 4.60--4.30 (1H, m), 4.254.00 (1H, m), 4.00-3.75 (3H, m), 3.654 (3H, s), 3.11 (2H, d); ultraviolet absorption (ethanol solution): Amax[max]; 205[126400], 226[94000], 268[5730], 274[6990], 282[6060] m .
(2) 16-(3-chlorophenoxy)-17,18,19,20-tetranor-cis-53-PGF2n methyl ester TLC (developing solvent, chloroform-methanol = 5:1, using a silica gel plate pretreated with AgNO3, twice development): Rf = 0.43;
NMR (CDCI3 solution): o; 7.256.68 (4H, m), 6.68-5.20 (6H, m), 4.60-4.30 (IH, m), 4.30--3.75 (4H, m), 3.663 (3H, s), 3.19 (2H, d); ultraviolet absorption (ethanol solution): Amax[Emax], 205[45480], 227[35800] 269[2230], 275[2880], 282[2622] m,u.
EXAMPLE 8.
Methyl 9α, 11α, 15α-trihydroxy- 1 6-phenoxy- 17,18,1 9,20-tetranorprosta-trans-3,cis- 5,trans-13-trienoate [or 16-phenoxy-17,18,19,20-tetranor-trans-#3-PGF2α methyl ester] and methyl 9α, 11α, 15α-trihydroxy- 16-phenoxy- 17,18,19,20-tetranorprosta- cis-3,cis-5,trans- 13-trienoate [or 16-phenoxy- 17,18,19,20-tetranor-cis-A3-PGF2,, methyl ester]
28 mg of methyl 9α,11α,15α -trihydroxy-16-phenoxy- 17,18,19,20-tetranorprosta- trans and cis-3,cis-5,trans-13-trienoate (prepared as described in Example 5) were separated by thin layer chromatography on silica gel pre-treated with silver nitrate developing three times with a mixture of chloroform and ethanol (5:1) as developing solvent to give 3 mg of the trans-A3-compound, 2
EXAMPLE 10.
9α,11α,15α-Trihydroxyprosta-trans and cis-3,trans-13-dienoic acid [or trans and cs-A3-PGF,a] A solution of 322 mg of 9a,l la,15a-tris(2-tetrahydropyranyloxy)prosta-trans and cis-3,trans-13-dienoic acid (prepared as described in Example 9) in a mixture of 0.5 ml of tetrahydrofuran and 5 ml of 65% aqueous acetic acid was stirred at 45 C for two hours, the reaction mixture was diluted with ethyl acetate, washed with water and an aqueous solution of sodium chloride, dried over sodium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of cyclohexane and ethyl acetate (1:2) as eluent to give 96 mg of the title compound having the following physical characteristics: TLC (developing solvent, ethyl acetate-formic acid = 400:5): Rf = 0.18;
IR (liquid film): v; 3320, 2940, 2860, 1710, 1460, 1405, 1210, 1120, 1030, 970 cm-1 NMR (CDCI3 + acetone - d8 solution): o; 5.84-5.23 (4H, m), 4.65 (4H, broad s), 4.32-3.70 (3H, m), 3.25-2.88 (2H, m).
EXAMPLE 11.
Methyl 9a-hydroxy- 11 a, I 5a-bis(2-tetrahydropyranyloxy)- 16,1 6-dimethylprosta- trans and cis-3,trans- I 3-dieonate By proceeding as described in Example 4, but replacing the methyl 9a, 11 a, I 5a trihydroxy - 16 - (3 - trifluoromethylphenoxy) - 17,18,19,20 - tetranorprosta - trans 2,cis-5 ,trans- 1 3-trienoate by 470 mg of 9a-hydroxy- 11 a, I 5a-bis(2-tetrahydro- pyranyloxy)- 16,1 6-dimethylprosta-trans-2,trans- I 3-dienoic acid (prepared as described in our British Patent Specification No. 1,540,427), there was obtained 9ahydroxy - I la,l5a - bis(2 - tetrahydropyranyloxy) - 16,16 - dimethylprosta-trans and cis-3,trans-13-dienoic acid. To a solution of the 9a-hydroxy-l la,15a-bis(2- tetrahydropyranyloxy)- 16,1 6-dimethylprosta-trans and cis-3 ,trans- I 3-dienoic acid obtained, in a mixture of ethyl acetate and diethyl ether, was added a freshly prepared ethereal solution of diazomethane at 0 C until the reaction mixture turned pale yellow. The reaction mixture was concentrated under reduced pressure at a low temperature, and the residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (4:1) as eluent to give
175 mg of the title compound having the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.39;
IR (liquid film): v; 3450, 1740, 1440, 1020, 980 cm-';
NMR (CDCI3 solution): ô; 5.60=5.20 (4H, m), 4.70--4.43 (2H, m), 3.61 and 3.60 (3H, each s), 3.16-2.85 (2H, m).
EXAMPLE 12.
Methyl 9-oxo- 11 a, 1 5a-bis(2-tetrahydropyranyloxy)- 16,1 6-dimethylprosta-trans and cis-3,trans- 1 3-dienoate
To a suspension of 208 mg of N-chlorosuccinimide in 6.5 ml of toluene were added 0.272 ml of dimethyl sulphide at -200C, and the mixture was stirred for
1.5 hours at -200C. To the solution was added a solution of 175 mg of methyl 9a- hydroxy- 11 a,15-bis(2-tetrahydropyranyloxy)- 16,16-dimethylprosta-trans and cis3,trans-13-dienoate (prepared as described in Example 11) in 4 ml of toluene, and the mixture was stirred for two hours at 200 C. To the solution thus obtained was added a solution of 0.39 ml of triethylamine in I ml of n-pentane with stirring.
Stirring was continued for 10 minutes at room temperature. The reaction mixture was extracted with ethyl accetate, and the extract was washed with water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (9:1) as eluent to give 130 mg of the title compound having the following physical charac teristics:- TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.65;
IR (liquid film): v; 1740, 1710, 1440, 1040, 980 cm-';
NMR (CCI4 solution): ö; 5.80=5.35 (4H, m), 4.88=4.45 (2H, m), 3.63 (3H, s).
EXAMPLE 13.
Methyl 9-oxo-11,15-dihydroxy-16,16-dimethylprosta-trans and cis-3,trans-13dienoate [or 16,16-dimethyl-trans and cis-53-PGE, methyl ester]
By proceeding as described in Example 10, but replacing the 9a,l la,15a- tris-(2-tetrahydropyranyloxy)-prosta-trans and cis-3,trans- 1 3-dienoic acid by 130 mg of methyl 9-oxo- II a, I 5a-bis(2-tetrahydropyranyloxy)- 16,1 6-dimethylprosta-trans and cis-3,trans-l 3-dienoate (prepared as described in Example 12), there were obtained 60 mg of the title compound having the following physical charac teristics:- TLC (developing solvent, ethyl acetate): Rf = 0.26; IR (liquid film): v; 3450, 1740, 1440, 1160, 980 cam~'; NMR (CDCI3 solution): o; 5.90=5.35 (4H, m), 4.10--3.70 (2H, m), 3.65 (3H, s), 3.10=2.93 (2H, m), 2.87-2.55 (1H, m), 1.05--0.70 (9H, m).
REFERENCE EXAMPLE 8.
2a-(6 - Methoxycarbonylhex-trans- 5 -enyl)- 3p-benzoyloxymethyl-4-(2-tetrahydro-
pyranyloxy)cyclopentan- 1 a-ol To a solution of 3.1 g of 2a-(6-methoxycarbonylhex-trans-5-enyl)-3p-hydroxy methyl-4a-(2-tetrahydropyranyloxy)cyclopentan - 1 a- ol (prepared as described hereafter) in a mixture of 30 ml of methylene chloride and 4.45 ml of pyridine was added dropwise over a period of one hour a solution of 1.4 ml of benzoyl chloride in 25 ml of methylene chloride at 250 to -200C with stirring. Stirring of the mixture was continued for I hour at the same temperature. The reaction mixture was quenched with an aqueous solution of sodium bicarbonate, and extracted with ethyl acetate. The extract was washed with cold IN hydrochloric acid, water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure to give 4.1 g of the crude title compound having the following physical characteristic: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.36.
2 - (6 - Methoxycarbonylhex - trans - 5 - enyl) - 3p - hydroxymethyl - 4 - (2- tetrahydropyranyloxy)cyclopentan-l-ol used as a starting material in the above procedure, was prepared as described in our British Patent Specification No.
1,540,427.
REFERENCE EXAMPLE 9.
I a,4a- B is(2 -tetrahydropyranyloxy)-2-(6- methoxycarbonylhex-trans- 5 -enyl)- 3p- benzoyloxymethylcyclopentane
By proceeding as described in Reference Example 2, but replacing the methyl 9-acetoxy- 11 a-(2-tetrahydropyranyloxy)- 1 5a-hydroxy- I 7-phenyl- 18,19,20- trinorprosta-cis-5,trans- 1 3-dienoate by 4.1 g of 2-(6-methoxycarbonylhex-trans-5- enyl)- 3A- benzoyloxymethyl -4-(2-tetrahydropyranyloxy)cyclopentan - I - ol (prepared as described in Reference Example 8), there were obtained 5.0 g of the crude title compound having the following physical characteristic:- TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.73.
REFERENCE EXAMPLE 10.
1 a ,4a- B is(2-tetrahydropyranyloxy)-2-(6-carboxyhex-trans- 5 - enyl)- 3p-hydroxy
methylcyclopentane
A solution of 5.0 g of 1a,4a-bis(2-tetrahydropyranyloxy)-2a-(6-methoxy- carbonylhex-trans-5-enyl)-3p-benzoyloxymethylcyclopentane (prepared as described in Reference Example 9) in 35 ml of ethanol was stirred with 40 ml of a 5% (w/v) aqueous potassium hydroxide solution at 50"C for 1.5 hours. The reaction mixture was acidified to pH 3 to 4 with an aqueous solution of oxalic acid, extracted with ethyl acetate, and the extract was washed with water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (2:1) as eluent to give 2.8 g of the title compound having the following physical characteristics: TLC (developing solvent, chloroform-tetrahydrofuran-acetic acid = 10:2:1):
Rf = 0.54;
IR (liquid film): v; 1730--1700, 1020 cm-1;
NMR (CDCI3 solution): o; 7.30-6.65 (3H, m), 5.82 (IH, d), 4.92=4.50 (2H, m).
REFERENCE EXAMPLE 11.
la,4a - Bis - (2 - tetrahydropyranyloxy) - 2a - (6 - methoxycarbonylhex - trans - 5 e nyl)-3p-hydroxymethyIcyclope ntan e To a solution of 1.5 g of ia,4a-bis(2-tetrahydropyranyloxy)-2a-(6-carboxyhex- trans-5-enyl)-3,B-hydroxymethylcyclopentane (prepared as described in Reference
Example 10) in a mixture of 25 ml of ethyl acetate and 25 ml of diethyl ether, was added a freshly prepared ethereal solution of diazomethane at OOC until the reaction mixture turned pale yellow. The reaction mixture was then concentrated under reduced pressure at a low temperature to give 1.53g of the crude title compound having the following physical characteristic TLC (developing solvent, benzene-ethyl acetate = 1:1): Rf = 0.40.
REFERENCE EXAMPLE 12.
la,4a - Bis(2 - tetrahydropyranyloxy) - 2a - (6 - methoxycarbonylhex - trans - 5
enyl)-3p-formylcyclopentane
Under an atmosphere of nitrogen, 4.2 g of chromium trioxide were added to a solution of 6.65 ml of pyridine in 100 ml of methylene chloride with stirring and the mixture was then stirred for 10 minutes at room temperature. 20 g of infusorial earth were added to the solution, and then there was added a solution of 1.53 g of 1a,4a-bis(2-tetrahydropyranyloxy)-2a-(6-methoxycarbonylhex-trans-5- enyl)-3A-hydroxymethylcyclopentane (prepared as described in Reference
Example II) in 30 ml of methylene chloride at 100C. After stirring for 10 minutes 35 g of sodium bisulphate monohydrate were added to the reaction mixture and stirring was continued for a further 15 minutes. The resulting precipitate was filtered off using a pad of magnesium sulphate and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (5:1) as eluent to give 1.09 g of the title compound having the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.66;
IR (liquid film): v 1730, 1660, 1440, 1240, 1020 cam~'; NMR (CDCI3 solution): 6; 9.90=9.72 (1H, m), 6.94 (IH, dt), 5.82 (1H, d), 4.924.50 (2H, m), 3.70 (3H, s).
REFERENCE EXAMPLE 13.
Methyl 9a a-bis(2-tetrahydropyranyloxy)- 15 -oxo- 16 -phenoxy- 17,18,1 9,20-tetra- norprosta-trans-2,trans- 1 3-dienoate Under an atmosphere of nitrogen, a solution of 940 mg of dimethyl 2-oxo-3phenoxypropylphosphonate in 3 ml of anhydrous tetrahydrofuran were added dropwise to a suspension of 114 mg of sodium hydride (63% content) in 20 ml of anhydrous tetrahydrofuran at room temperature, and the mixture was stirred at that temperature until a clear solution was obtained. To the solution was added a solution of 930 mg of 1a,4a-bis(2-tetrahydropyranyloxy)-2a-(6-methoxycarbonyl hex-trans-5-enyl)-3,B-formylcyclopentane (prepared as described in Reference
Example 12) in 3 ml of anhydrous tetrahydrofuran, and the mixture was stirred at room temperature for 30 minutes and then at 600 to 650C for 2 hours. The reaction mixture was then neutralized with acetic acid, filtered through a pad of silica gel, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (5:1) as eluent to give 850mg of the title compound having the following physical characteristics: IR (liquid film): v; 1730, 1690, 1600, 1500, 1140, 1030, 980 cam~'; NMR (CDCI3 solution): ô; 7.456.30 (8H, m), 5.82 (1H, d), 4.90--4.40 (4H, m),
3.70 (3H, s).
* REFERENCE EXAMPLE 14.
Methyl 9a a-bis(2-tetrahydropyranyloxy)- 155-hydroxy- 16-phenoxy- 17,18,19,20
tetranorprosta-trans-2,trans- 1 3-dienoate
To a solution of 850 mg of methyl 9a,lla-bis(2-tetrahydropyranyloxy)-15- oxo-16-phenoxy- 17,18,19,20-tetranorprosta-trans-2,trans- 13-dienoate (prepared as described in Reference Example 13) in 12 ml of absolute methanol were added 190 mg of sodium borohydride at -400 to -500C and the mixture was stirred at the same temperature for 15 minutes. After quenching with acetic acid, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with an aqueous solution of sodium bicarbonate, water and an aqueous solution of sodium chloride, dried over magnesium sulphate and concentrated under reduced pressure to give 850 mg of the crude title compound having the following physical characteristics: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.47 and 0.51;
NMR (CDCI3 solution): ô; 7.50=6.65 (6H, m), 5.92-5.50 (3H, m), 4.904.35 (3H, m), 3.70 (3H, s).
EXAMPLE 14.
Methyl 9a a-bis(2-tetrahydropyranyloxy)- 1 5-hydroxy- I 6-phenoxy- 17,18,19,20
tetranorprosta-trans and cis-3,trans- 1 3-dienoate By proceeding as described in Example 4, but replacing the methyl 9a, II a, iSa- trihydroxy - 16 - (3 - trifluoromethylphenoxy) - 17,18,19,20 - tetranorprosta - trans 2,cis-5,trans-l3-trienoate by 368 mg of methyl 9a,l la-bis(2-tetrahydropyranyloxy)- 15# - hydroxy - 16 - phenoxy - 17,18,19,20 - tetranorprosta - trans - 2,trans - 13 dienoate (prepared as described in Reference Example 14), there were obtained 210 mg of the title compound having the following physical characteristics: NMR (CDCI3 solution): oA; 7.52-6.70 (5H, m), 5.95-5.40 (4H, m), 4.85=4.30 (3H, m), 3.66 (3H, s).
EXAMPLE 15.
Methyl 9α,11α,15α-trihydroxy-16-phenoxy- 17,18,19,20-tetranorprosta-trans and cis-3,trans- I 3-dienoate [or 16-phenoxy-17,18,19,20-tetranor-trans and cis-53-PGF" methyl ester]
By proceeding as described in Example 10, but replacing the 9a,1 la,15a-tris(2- tetrahydropyranyloxy)-prosta-trans and cis-3,trans- 1 3-dienoic acid by 177 mg of methyl 9α,11α-bis(2-tetrahydropyranyloxy)- 1 5g- hydroxy- 1 6-phenoxy- 17,18,19,20tetranorprosta-trans and cis-3 ,trans- 1 3-dienoate (prepared as described in Example 14), there were obtained 41 mg of the title compound, 30 mg of its 15ss-hydroxy isomer and 10 mg of their mixture. The title compound showed the following physical characteristics: TLC (developing solvent, ethyl acetate): Rf = 0.13 (15ss-hydroxy isomer, Rf = 0.18); IR (liquid film): v; 3400, 1740, 1600, 1590, 1500, 1250, 980, 760 cm-1;
NMR (CDCI3 solution): ô; 7.38--6.80 (5H, m), 5.72-5.40 (4H, m), 4.58=4.34 (1H, m) 4.27-3.80 (4H, m), 3.65 and 3.64 (3H, each s), 3.12-2.90 (2H, m).
EXAMPLE 16.
Methyl 9α, 11α, 15α-tris(2-tetrahydropyranyloxy)- 16-phenoxy- 17,18,19,20-tetranor- prosta-trans and cis-3,cis-5,trans-13-trienoate
By proceeding as described in Reference Example 2, but replacing the methyl 9a-acetoxy- 11 a-(2-tetrahydropyranyloxy)- 1 Sa-hydroxy- I 7-phenyl- 18,19,20trinorprosta-cis-5,trans-13-dienoate by 43 mg of methyl 9a, 11 a, I Sa-trihydroxy- 16- phenoxy- 17,18,19,20-tetranorprosta-trans and cis-3 ,cis-5,trans-13-trienoate (prepared as described in Example 5), there were obtained 70 mg of the title compound having the following physical characteristic: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.63.
EXAMPLE 17.
Methyl 9a, 11 a, 1 Sa-trihydroxy- 16-phenoxy- 17,18, 19,20-tetranorprosta-trans-3,trans- 5,trans- I 3-trienoate
A solution of 70 mg of methyl 9α, 11α, 15α-tris(2-tetrahydropyranyloxy)- 16- phenoxy-17,18,19,20-tetranorprosta-trans and cis-3,cis-5,trans- 1 3-trienoate (prepared as described in Example 16) in 2 ml of carbon tetrachloride was treated with 0.012 ml of a 0.1N solution of iodine in carbon tetrachloride. The reaction mixture was allowed to stand in a glass-stoppered Pyrex flask exposed to ordinary diffuse laboratory light at room temperature for 25 hours, and the solvent was then evaporated by a stream of nitrogen to give methyl 9a,l la,15a-tris(2-tetra- hydropyranyloxy) - 16 - phenoxy - 17,18,19,20 - tetranorprosta - trans - 3,trans 5,trans-13-trienoate. ("Pyrex is a registered Trade Mark). The compound thus obtained was dissolved in 2 ml of methanol, and a small amount of p-toluenesulphonic acid was added. The reaction mixture was stirred at 400C for 30 minutes, diluted with diethyl ether, washed with an aqueous solution of sodium chloride, dried over sodium sulphate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a mixture of benzene and ethyl acetate (1:2) as eluent to give 14.4 mg of the title compound having the following physical characteristics: TLC (developing solvent, chloroform-ethanol = 5:1): Rf = 0.42; IR (CHCl2 solution): #; 3420, 3020, 1733, 1601, 1589, 1454, 1244, 1040, 992, 974 cm-1;
NMR (CDCI3 solution): #; 7.4-7.1 (2H, m), 7.1--6.8 (3H, m), 6.4-5.2 (6H, m), 4.47 (1H, m), 4.12 (1H, m), 3.91 (2H, m), 3.65 (3h, s).
EXAMPLE 18.
Methyl 9a, 11 a, I 5a-tris(2-tetrahydropyranyloxy)- 16-(3-chlorophenoxy)- 17,18,19,20- tetranorprosta-trans and cis-3,cis-5,trans-l 3-trienoate By proceeding as described in Reference Example 2, but replacing the methyl 9a-acetoxy- II a-(2-tetrahydropyranyloxy)- I Sa-hydroxy- 1 7-phenyl- 18,19,20- trinorprosta-cis-5,trans-13-dienoate by 52 mg of methyl 9a,l ,15a-trihydroxy-16- (3 - chlorophenoxy) - 17,18,19,20 - tetranorprosta - trans and cis - 3,cis - 5,trans1 3-trienoate (prepared as described in Example 2), there were obtained 82 mg of the title compound having the following physical characteristic: TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.58.
EXAMPLE 19.
Methyl 9a, II a, 1 Sa-trihydroxy- 1 6-(3 -chlorophenoxy)- 17,18,1 9,20-tetranorprosta- trans-3 ,trans-5,trans-l 3-trienoate
By proceeding as described in Example 17, but replacing the methyl 9a,l la,l5a - tris(2 - tetrahydropyranyloxy) - 16 - phenoxy - 17,18,19,20 - tetranorprosta-trans and cis-3,cis-5,trans-l3-trienoate by 82 mg of methyl 9a,l la,l5a-tris(2- tetrahydropyranyloxy)- 16-(3 -chlorophenoxy)- 17,18,1 9,20-tetranorprosta-trans and cis-3,cis-5,trans-13-trienoate (prepared as described in Example 18), there were obtained 28 mg of the title compound having the following physical characteristics:
TLC (developing solvent, chloroform-ethanol = 5:1): Rf = 0.36; IR (CHCl3 solution): v; 3400, 3020, 1731, 1596, 1582, 1476, 997, 976 cam~'; NMR (CDCI3 solution): o; 7.4-6.7 (4H, m), 6.4-5.2 (6H, m), 4.45 (1H, m), 4.14 (1H, m), 3.9 (2H, m), 3.66 (3H, d).
EXAMPLE 20.
A-Cyclodextrin clathrate of methyl 9a, 11 a, I Sa-trihydroxy- 1 6-(3-chlorophenoxy)- 17,18,1 9,20-tetranorprosta-trans and cis-3,cis-5,trans-l 3-trienoate [or p-cyclodextrin
clathrate of 16-(3-chlorophenoxy)- 17,18, 19,20-tetranor-trans and cis-A3-PGF2, methyl ester]
A solution of 3.38 mg of methyl 9a,11ct,15 < r-trihydroxy-16-(3-chlorophenoxy)- 17,18,1 9,20-tetranorprosta-trans and cis-3,cis-5,trans- I 3-trienoate (prepared as
described in Example 2) in 1 ml of ethanol was added to a solution of 35.68 mg of P- cyclodextrin in 1.5 ml of water and the mixture was stirred at room temperature for
5 minutes. The mixture was concentrated under reduced pressure to give 39 mg of the p-cyclodextrin clathrate of the compound specified in the title. The content of
prostaglandin analogue in the product was 8.68%.
The compounds used as starting materials in Examples 1, 2, 4, 5 and 6 may be prepared as described in our British Patent Specification No. 1,521,747.
The present invention includes within its scope pharmaceutical compositions which comprise at least one new therapeutically useful compound of general formula VI, or cyclodextrin clathrate or non-toxic salt thereof, together with a pharmaceutical carrier or coating. In clinical practice the new compounds of the present invention will normally be administered orally, vaginally, rectally or parenterally.
Solid compositions for oral -administration include compressed tablets, pills, dispersible powders, and granules. In such solid compositions one or more of the active compounds is, or are, admixed with at least one inert diluent such as calcium carbonate, potato starch, alginic acid, mannitol or lactose. The compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate. Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water and liquid paraffin. Besides inert diluents such compositions may also
comprise adjuvants, such as wetting and suspending agents, and sweetening,
flavouring, perfuming and preserving agents. The compositions according to the
invention, for oral -administration, also include capsules of absorbable material
such as gelatin containing one or more of the active substances with or without the
addition of diluents or excipients.
Solid compositions for vaginal administration include pessaries formulated in
manner known per se and containing one or more of the active compounds.
Solid compositions for rectal administration include suppositories formulated
in manner known per se and containing one or more of the active compounds.
Preparations according to the invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. These compositions may also include adjuvants such as preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation of sterilising agents in the compositions or by irradiation. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage for the therapeutic effect desired shall be obtained. Obviously several unit dosage forms may be administered at about the same time. In general, the preparations should normally contain at least 0.025% by weight of active substance when required for administration by injection; for oral administration the preparations will normally contain at least 0.1% by weight of active substance.
The dose employed depends upon the desired therapeutic effect, the route of administration and the duration of the treatment.
In the human adult female the doses per person are generally between 0.001 and 50 mg by oral, intravaginal, intravenous and extra-amniotic administration for contraception and menstrual regulation and in the termination of pregnancy and the induction of labour in pregnant females. In domestic female mammals, such as cows, mares, sows, ewes and bitches, the doses are generally between 0.001 and 50 mg/animal by intramuscular, subcutaneous, intrauterine, intravaginal or intravenous administration for the synchronisation of oestrus, treatment of impaired fertility and the induction of abortion and of labour.
The following Example illustrates pharmaceutical compositions according to the invention.
EXAMPLE 21.
Methyl 9a, 1 la,lSa-trihydroxy- 16-(3-chlorophenoxy)- 17,18,19,20-tetranorprosta-trans and cis-3,cis-5,trans-13-trienoate (2 mg) was dissolved in ethanol (10 ml), mixed with mannitol (18.5 g), sieved through a 30-mesh sieve, dried at 30"C for 90 minutes and again sieved through a 30-mesh sieve. Aerosil (microfine silica, 200 mg) was
Claims (55)
1. Prostaglandin analogues of the general formula:
[wherein X represents cis or trans-vinylene or ethylene, Z represents
R' represents a hydrogen atom or a straight- or branched-chain alkyl group containing from I to 12 carbon atoms, R2 represents a hydrogen atom or a methyl group, R3 represents a straight- or branched-chain alkylene group containing from 1 to 7 carbon atoms and R4 represents a cycloalkyl group containing from 5 to 7 carbon atoms, a grouping of the formula:
(wherein R5 and RB, wich may be the same or different, each represent a hydrogen atom or halogen atom, a trifluoromethyl group or a straight- or branched-chain alkyl group containing from I to 4 carbon atoms), or a grouping of the formula:
(wherein R5 and R6 are as hereinbefore defined), or R3 and R4 together represent a straight- or branched-chain alkyl group containing from 1 to 10 carbon atoms, and (I) the double bond between C3-C4 is trans or cis, or trans and cis, when X is cs- vinylene or ethylene, and (2) the double bond between C2-C4 is trans, when X is trans-vinylene, and the double bond between C,3C,4 is trans, with the exclusion of those prostaglandin analogues wherein X represents cis-vinylene or ethylene, Z represents C=O, R' and R2 represent hydrogen atoms, R3 and R4 together represent n-pentyl and the double bond between C3-C4 is trans] and cyclodextrin clathrates of such acids and esters, and when R' represents a hydrogen atom, nontoxic salts thereof.
2. Prostaglandin analogues according to claim 1 wherein X is other than ethylene, the double bond between C13-C14 is trans, and the other symbols are as defined in claim 1, and cyclodextrin clathrates of such acids and esters, and when
R' represents a hydrogen atom, non-toxic salts thereof.
3. Prostaglandin analogues according to claim I wherein X represents cisvinylene, the double bond between C3-C4 is trans or cis, or trans and cis, the double bond between C13-C14 is trans and the other symbols are as defined in claim 1, and cyclodextrin clathrates of such acids and esters, and when R' represents a hydrogen atom, non-toxic salts thereof.
4. Prostaglandin analogues according to claim 1, 2 or 3 wherein R' represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms.
5. Prostaglandin analogues according to claim 4 wherein R' represents a hydrogen atom or a methyl group.
6. Prostaglandin analogues according to any one of the preceding claims wherein R2 represents a hydrogen atom.
7. Prostaglandin analogues according to any one of the preceding claims wherein R3 represents methylene or ethylene and R4 represents a grouping of formula VII or VIII depicted in claim I in which RB represents a hydrogen atom and Re represents a hydrogen atom or a chlorine atom or a trifluoromethyl group, or R3 and R4 together represent a pentyl group or a l,l-dimethylpentyl group.
8. Prostaglandin analogues according to any one of the preceding claims wherein the hydroxy groups depicted in formula VI in claim 1 in a- or configuration are attached to the carbon atom in a-configuration.
9. Methyl 9a,l la,lSa - trihydroxy - 16 - (3 - trifluoromethylphenoxy) 17,18,1 9,20-tetranorprosta-trans and cis-3,cis-5,trans- I 3-trienoate.
10. Methyl 9a,lla,l5a - trihydroxy - 16 - (3 - chlorophenoxy) - 17,18,19,20 tetranorprosta-trans and cis-3,cis-5,trans-13-trienoate.
II. Methyl 9a,11ct,15a - trihydroxy - 17 - phenyl - 18,19,20 - trinorprosta trans and cis-3,cis-5,trans-13-trienoate.
12. Methyl 9a,lla,lja - trihydroxy - 16 - phenoxy - 17,18,19,20 - tetranor prosta-trans and cis-3 ,cis-5 ,trans- 1 3-trienoate.
13. Methyl 9a,lla,l5a - trihydroxy - 16 - (4 - chlorophenoxy) - 17,18,19,20 tetranorprosta-trans and cis-3,cis-5,trans-l3-trienoate.
14. Methyl 9a,lla,l5a - trihydroxy - 16 - (3 - chlorophenoxy) - 17,18,19,20) tetranorprosta-trans-3,cis-5,trans- 13-trienoate.
15. Methyl 9a,lla,l5a - trihydroxy - 16 - (3 - chlorophenoxy) - 17,18,19,20 tetranorprosta-cis-3,cis-5,trans-l 3-trienoate.
16. Methyl 9a lla,15a - trihydroxy - 16 - phenoxy - 17,18,19,20 - tetranor prosta-trans-3,cis-5,trans-l 3-trienoate.
17. Methyl 9a,lla,l5a - trihydroxy - 16 - phenoxy - 17,18,19,20 - tetranor prosta-cis-3,cis-5,trans- 1 3-trienoate.
18. 9α,11α,15α-Trihydroxyprosta-trans and cis-3,trans- 1 3-dienoic acid.
19. Methyl 9 - oxo - I la,l5a - dihydroxy - 16,16 - dimethylprosta - trans and cis-3 ,trans- 1 3-dienoate.
20. Methyl 9a,l Ia,l5a - trihydroxy - 16 - phenoxy - 17,18,19,20 - tetranor prosta-trans and cis-3,trans- I 3-dienoate.
21. Methyl 9a,lla,l5a - trihydroxy - 16 - phenoxy - 17,18,19,20 - tetranor prosta-trans-3,trans-5,trans- 13-trienoate.
22. Methyl 9a,I la,15a - trihydroxy - 16 - (3 - chlorophenoxy) - 17,18,19,20 tetranorprosta-trans-3,trans-5,trans- 13-trienoate.
23. ss-Cyclodextrin clathrate of methyl 9α, 11α, 15α-trihydroxy- 16-(3-chloro- phenoxy)- 17,18,1 9,20-tetranorprosta-trans and cis-3,cis-5,trans- 1 3-trienoate.
24. Non-toxic salts of a prostaglandin analogue as claimed in any one of claims I to 8, wherein R' in general formula VI depicted in claim 1 represents a hydrogen atom, or in claim 18.
25. Cyclodextrin clathrates of a prostaglandin analogue as claimed in any one of claims 1 to 22.
26. Process for the preparation of prostaglandin analogues as claimed in claim 1 and conforming to the general formula:
(wherein Y represents cis-vinylene or ethylene, R7 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms, Z, R2,
R3 and R4 are as defined in claim 1, the double bond between CCa is trans or cis, or trans and cis, and the double bond between C13-C14 is trans) which comprises hydrolysing a cyclopentane derivative of the general formula:
(wherein RB represents a 2-tetrahydrofuranyl group or a l-ethoxyethyl group or a 2tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group, RB represents a hydrogen atom or a 2-tetrahydrofuranyl group or a l-ethoxyethyl group or a 2-tetrahydropyranyl group unsubstituted or substituted by at least one alkyl group, RB being other than hydrogen when Z represents
Y and R7 are as hereinbefore defined, Z, R2, R3 and R4 are as defined in claim I, the double bond between C2-C4 is trans or cis, or trans and cis and the double bond between C,3C,4 is trans) to convert to a hydroxy group the group ORB and, when
RB is other than a hydrogen atom, the group OR9.
27. Process for the preparation of prostaglandin analogues as claimed in claim 1 and conforming to the general formula:
(wherein Y and R7 are as defined in claim 26, R2, R3 and R4 are as defined in claim 1, the double bond between C2-C4 is trans or cis, or trans and cis and the double bond between C,3C,4 is trans) which comprises hydrolysing a compound of the general formula:
(wherein Y, R7 and RB are as defined in claim 26, R2, R3 and R4 are as defined in claim 1, the double bond between C3-C4 is trans or cis, or trans and cis and the double bond between C,3C,4 is trans) to convert to hydroxy groups the groups OR8.
28. Process for the preparation of prostaglandin analogues as claimed in claim
I and conforming to the general formula:
(wherein R7 is as defined in claim 26, X, R2, R3 and R4 are as defined in claim I, the double bond between C3-C4 is trans or cis, or trans and cis, when X is cis-vinylene or ethylene, and the double bond between C2-C4 is trans when X is trans-vinylene, and the double bond between C13-C14 is trans) which comprises hydrolysing a compound of the general formula:
(wherein R7 and R8 are as defined in claim 26, X, R2, R3 and R4 are as defined in claim 1, and the double bonds between C2-C4 and C,3C,4 are as hereinbefore specified in relation to formula VIA) to convert to hydroxy groups the groups ORB.
29. Process according to claim 26, 27 or 28 wherein the symbols R8 and, when a group OR8 is present, the symbol RB, represent the 2-tetrahydropyranyl group.
30. Process according to any one of claims 26 to 29 in which the hydrolysis of the group OR8 and, when a group OR8 is present and RB is other than a hydrogen atom of the group OR8, is effected with an aqueous solution of an organic acid or with a dilute aqueous inorganic acid at a temperature from ambient to 750 C.
31. Process according to claim 30 in which the hydrolysis is effected in the presence of an inert organic solvent miscible with water.
32. Process according to any one of claims 26 to 29 in which the hydrolysis of the group OR8 and, when a group OR8 is present and Rub is other than a hydrogen atom, of the group OR8, is effected with an anhydrous solution of an organic acid at a temperature from 10 to 450C.
33. Process for the preparation of prostaglandin analogues as claimed in claim
I and conforming to the general formula:
(wherein Y and R7 are as defined in claim 26, R2, R3 and R4 are as defined in claim 1, the double bond between C3-C4 is trans or cis, or trans and cis, and the double bond between C13-C14 is trans) which comprises the reaction of a compound of the general formula:
(wherein Y and R7 are as defined in claim 26, R2 R3 and R4 are as defined in claim 1, and the double bonds between C2-C3 and C13-C14 are trans) (i) with an alkali metal hydroxide or carbonate in the presence of an inert organic solvent at a temperature from ambient to -20 C, or (ii) with equimolecular quantities of a lithium compound of the general formula:
(wherein R'O and R", which may be the same or different, each represent a straight- or branched-chain alkyl group containing from I to 6 carbon atoms or a cycloalkyl group containing from 3 to 6 carbon atoms) and hexamethylphosphoramide in the presence of an inert organic solvent at a low temperature.
34. Process according to claim 33 in which the compound of general formula
XIII is reacted (i) with sodium or potassium hydroxide or carbonate in an alkanol containing from I to 4 carbon atoms or (ii) with equimolecular quantities of lithium diisopropylamide and hexamethylphosphoramide in tetrahydrofuran at -700C.
35. Process for the preparation of prostaglandin analogues as claimed in claim 1 and conforming to the general formula:
(wherein R7 is as defined in claim 26, X, R2, R3 and R4 are as defined in claim 1, the double bond between C3-C4 is trans or cis, or trans and cis, when X is cis-vinylene
or ethylene, and the double bond between C3-C4 is trans when X is trans-vinylene,
and the double bond between C,3C,4 is trans) which comprises hydrolysing the silyloxy groups of a compound of the general formula:
(wherein TMS represents the trimethylsilyl group, R7 is as defined in claim 26, X,
R2, R3 and R4 are as defined in claim I, and the double bonds between C3-C4 and C13-C14 are as hereinbefore specified in relation to formula VIB) to hydroxy groups under extremely mild acidic conditions.
36. Process according to claim 35 in which the hydrolysis is effected by treament of a solution of the compound of general formula XIVA in ethyl acetate or diethyl ether with an aqueous oxalic acid solution at room temperature.
37. Process according to any one of claims 26 to 36 followed by the step of subjecting the prostaglandin analogues of general formula VI depicted in claim 1, wherein the double bond between C3-C4 is trans and cis, to thin layer chromatography on silica gel pre-treated with silver nitrate using an inert organic solvent medium as developing solvent to separate the prostaglandin analogues of general formula VI in which the double bond between C3-C4 is trans and the prostaglandin analogues of general formula VI in which the double bond between C3-C4 is cis.
38. Process according to claim 37 in which the inert organic solvent medium is chloroform and methanol or chloroform and ethanol.
39. Process according to any one of claims 26 to 38 followed by the step of converting by methods known per se a prostaglandin analcgue of general formula
VI depicted in claim 1, wherein R' represents a hydrogen atom, into a corresponding ester of that formula wherein R1 represents a straight- or branchedchain alkyl group containing from I to 12 carbon atoms.
40. Process according to any one of claims 26 to 38 followed by the step of converting by methods known per se a prostaglandin analogue of general formula
VI depicted in claim 1, wherein R' represents a hydrogen atom, into a non-toxic salt.
41. Process according to any one of claims 26 to 39 followed by the step of converting by methods known per se a prostaglandin analogue of general formula
VI depicted in claim 1 into a cyclodextrin clathrate.
42. Process for the preparation of prostaglandin analgoues of general formula
VI depicted in claim 1, wherein the various symbols are as defined in claim I, substantially as hereinbefore described with especial reference to Example 13.
43. Process for the preparation of prostaglandin analogues of general formula
VI depicted in claim 1, wherein the various symbols are as defined in claim 1 substantially as hereinbefore described with especial reference to Example 10, 17 or 19.
44. Process for the preparation of prostaglandin analogues of general formula
VI depicted in claim 1, wherein the various symbols are as defined in claim I, substantially as hereinbefore described with especial reference to Example 1, 2, 3, 4, 5 or 6.
45. Process for the preparation of prostaglandin analogues of general formula
VI depicted in claim 1, wherein the various symbols are as defined in claim 1, substantially as hereinbefore described with especial reference to Example 15.
46. Process according to claim 37 substantially as hereinbefore described with especial reference to Example 7 or 8.
47. Process according to claim 35 substantially as hereinbefore described.
48. Prostaglandin analogues of general formula VI depicted in claim 1, and cyclodextrin clathrates thereof and, when R' represents a hydrogen atom, nontoxic salts thereof, when prepared by the process claimed in any one of claims 26 to 47.
49. Pharmaceutical compositions which comprise as active ingredient, at least one prostaglandin analogue as claimed in any one of claims I to 22 and 48 or a cyclodextrin clathrate thereof or, when R' in general formula VI depicted in claim
I represents a hydrogen atom, a non-toxic salt thereof in association with a pharmaceutical carrier or coating.
50. Pharmaceutical compositions according to claim 49 substantially as hereinbefore described with especial reference to Example 21.
51. Compounds of the general formula:
wherein R2, R3, R4 and Z are as defned in claim I, Y, R7, R8 and R8 are as defined in claim 26, and the double bonds between C3-C4 and C13-C14 are as specified in claim 26 with the exclusion of those compounds wherein Z represents C=O, R7 and
R2 represent hydrogen atoms, R3 and R4 together represent n-pentyl and the double bond between C2-C4 is trans.
52. Compounds of the g general formula:
wherein R2, R1 and R4 are as defined in claim 1, Y, R' and RB are as defined in claim 26, and the double bonds between C3-C4 and C13-C14 are as specified in claim 26.
53. Compounds of the general formula:
wherein X, R2, R3 an I R4 are as defined in claim 1, R7 and R8 are as defined in claim 26, and the double bonds between C3-C4 and C,3C,4 are as specified in claim 28.
54. Compounds of the general formula:
wherein TMS represents the trimethylsilyl group, X, R2, R3 and R4 are as defined in claim 1, R7 is as defined in claim 26, and the double bonds between C2-C4 and
C13-C14 are as specified in claim 28 with the exclusion of those compounds wherein X represents cis-vinylene or ethylene, R7 and R2 represent hydrogen atoms, R3 and R4 together represent n-pentyl and the double bond between C3-C4 is trans.
55. A compound conforming to the general formula in claim 51, 52 or 53 and identified by name in Example 9, II, 12, 14, 16 or 18.
Reference has been directed in pursuance of section 9, subsection (1) of the
Patents Act 1949, to patents Nos. 1,483,240 and 1,416,410.
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB10118/76A GB1580201A (en) | 1976-03-12 | 1976-03-12 | Prostaglandin analogues |
| US05/774,828 US4145555A (en) | 1976-03-12 | 1977-03-07 | Δ3 -Prostaglandin analogs |
| DE2709804A DE2709804C2 (en) | 1976-03-12 | 1977-03-07 | Prostaglandin analogs, processes for their production, and pharmaceutical compositions containing them |
| FR7707098A FR2343728A1 (en) | 1976-03-12 | 1977-03-10 | PROSTAGLANDIN ANALOGUES, METHODS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING |
| AU23152/77A AU512595B2 (en) | 1976-03-12 | 1977-03-10 | Prostaglandin analogues |
| HU77OO238A HU178671B (en) | 1976-03-12 | 1977-03-10 | Process for producing new prostaglandine analogons |
| JP52025503A JPS5923305B2 (en) | 1976-03-12 | 1977-03-10 | Prostaglandin-like compounds |
| BE175715A BE852363A (en) | 1976-03-12 | 1977-03-10 | PROSTAGLANDIN ANALOGUES |
| CA273,659A CA1098124A (en) | 1976-03-12 | 1977-03-10 | Process for the preparation of prostaglandin analogues |
| IE526/77A IE45408B1 (en) | 1976-03-12 | 1977-03-10 | Prostagladin analogues |
| ZA00771462A ZA771462B (en) | 1976-03-12 | 1977-03-10 | Prostagladin analogues |
| NL7702620A NL7702620A (en) | 1976-03-12 | 1977-03-10 | PROCESS FOR PREPARING PROSTAGLAND INDEERI VESSELS. |
| CH313177A CH618681A5 (en) | 1976-03-12 | 1977-03-11 | Process for the preparation of prostaglandin analogues |
| DK106977A DK106977A (en) | 1976-03-12 | 1977-03-11 | PROSTAGLAND INNALOGUE PROCEDURE |
| LU76935A LU76935A1 (en) | 1976-03-12 | 1977-03-11 | |
| US05/934,444 US4165437A (en) | 1976-03-12 | 1978-08-17 | Δ3 -Prostaglandin analogs |
| JP59008444A JPS6023111B2 (en) | 1976-03-12 | 1984-01-23 | Prostaglandin-like compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB10118/76A GB1580201A (en) | 1976-03-12 | 1976-03-12 | Prostaglandin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1580201A true GB1580201A (en) | 1980-11-26 |
Family
ID=9961833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB10118/76A Expired GB1580201A (en) | 1976-03-12 | 1976-03-12 | Prostaglandin analogues |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS6023111B2 (en) |
| BE (1) | BE852363A (en) |
| GB (1) | GB1580201A (en) |
| ZA (1) | ZA771462B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4438106A (en) | 1981-07-16 | 1984-03-20 | Kureha Kagaku Kabushiki Kaisha | Inclusion compound of eicosapentaenoic acid or docosahexaenoic acid with cyclodextrin |
-
1976
- 1976-03-12 GB GB10118/76A patent/GB1580201A/en not_active Expired
-
1977
- 1977-03-10 BE BE175715A patent/BE852363A/en not_active IP Right Cessation
- 1977-03-10 ZA ZA00771462A patent/ZA771462B/en unknown
-
1984
- 1984-01-23 JP JP59008444A patent/JPS6023111B2/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4438106A (en) | 1981-07-16 | 1984-03-20 | Kureha Kagaku Kabushiki Kaisha | Inclusion compound of eicosapentaenoic acid or docosahexaenoic acid with cyclodextrin |
Also Published As
| Publication number | Publication date |
|---|---|
| BE852363A (en) | 1977-09-12 |
| JPS59144754A (en) | 1984-08-18 |
| ZA771462B (en) | 1978-02-22 |
| JPS6023111B2 (en) | 1985-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4128720A (en) | Prostaglandin analogues | |
| US4278688A (en) | Prostaglandin analogues | |
| US4087620A (en) | 15-Cycloalkyl-prostaglandin derivatives | |
| US4367237A (en) | Prostacyclin analogues | |
| US4024174A (en) | Tranes-delta 2-prostaglandins | |
| US4034003A (en) | 15-Cycloalkyl-prostaglandins | |
| US4562204A (en) | Trans-Δ2 -prostaglandin D derivatives, process for their preparation and compositions containing them | |
| US3953435A (en) | Aldehyde derivatives of prostaglandins | |
| US4052512A (en) | Prostaglandin analogues | |
| US4195182A (en) | Trans-Δ2 -prostaglandin analogues | |
| US4165437A (en) | Δ3 -Prostaglandin analogs | |
| US4145555A (en) | Δ3 -Prostaglandin analogs | |
| GB1580201A (en) | Prostaglandin analogues | |
| US4066751A (en) | Prostaglandin analogues | |
| US4208428A (en) | Prostaglandin analogues | |
| US4180675A (en) | 15-Cycloalkyl-prostaglandin derivatives | |
| US4390548A (en) | Trans-Δ2 -pge alkylsulphonyl amides | |
| US4065632A (en) | 16-Phenoxy and phenylthio prostaglandin derivatives | |
| US4275075A (en) | 15-cylobutyl-trans-Δ2 -prostaglandin analogues | |
| Hayashi et al. | Δ 3-Prostaglandin analogs | |
| US4070537A (en) | 17-Oxo-17-phenyl-prostaglandins | |
| JPH038337B2 (en) | ||
| US4110341A (en) | Dithio prostaglandin derivatives | |
| CA1098125A (en) | Process for the preparation of new prostaglandin analogues | |
| KR810000412B1 (en) | Process for the preparation of new prostaglandines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PCNP | Patent ceased through non-payment of renewal fee |